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Abstract 
 
Surgical Valve Replacement is the standard of care for patients with severe aortic valve 
calcification, which restricts blood flow from the left atrium to the rest of the body.  Valve calcification is 
common with aging but patients are often refused surgery due to comorbidities present.  Minimally 
invasive placement of tissue valves has recently been introduced to the market and has demonstrated 
applicability to patients not qualified for open heart surgery.  The purpose of this project is to design a 
self-expanding Nitinol stent with features to enable attachment to a polyurethane valve, facilitate 
deployment and repositioning as well as secure placement within the aortic annulus while avoiding 
obstruction of the aortic nodes. The design was performed in collaboration with Nitinol stent 
manufacturers, private consultants, and surgeons.  Various stent configurations were designed and 
ANSYS was used to conduct finite element analyses on the stent iterations.  The most promising stent 
design was ordered to be custom manufactured and the polyurethane valve was attached to the stent 
for deployment and bench-top performance testing. 
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Introduction 
Background and Significance 
Surgical Aortic Valve Replacement (AVR) is the standard of care for patients with severe aortic 
stenosis (AS) in which calcific disease has created an increase in valve leaflet stiffness. This causes a 
reduction in leaflet range of motion and the effective valve orifice area during systolic ejection (Chiam, 
Koh, & Chao, 2009). AS is common with aging and is the most common valve condition for which AVR is 
performed in the United States.  Standard indications for severe AS include symptoms such as external 
chest pain, syncope and dyspnea.  Once these symptoms develop, the average survival is 5, 3, and 2 
years, respectively (Varadarajan, 2006) and the only effective therapy is AVR.  Without surgical AVR, 
symptomatic patients have a 60% chance of seeing another year and a 32% chance of living an 
additional five years.  However, according to a study, the estimated operative mortality for a patient 
undergoing a routine AVR procedure is 4% and this number increases significantly with advanced patient 
age and the presence of comorbidities (Edwards, 2001).  Additionally, high-risk surgical patients due to 
pre-existing co-morbidities are not offered the treatment option of a surgical AVR and are left with no 
option other than a difficult adjustment to a relatively poor quality of life until they succumb to 
congestive heart failure.   
Transcatheter aortic valve implementation (TAVI) is a new technology specifically developed to 
address this high-risk population.  Bioprosthetic valves have been modified to allow their delivery to the 
aortic valve position using transcatheter techniques similar to those employed for the placement of 
balloon expandable stents to the coronary arteries.  One of the first generation stent-valves, the Cribier-
Edwards PHV (Cribier, 2006) consisted of three leaflets fabricated from horse tissue sewn onto a 
stainless steel balloon expandable stent as shown in .   
 
Figure 1.13: The Cribier-Edwards percutaneous bioprosthesis (Cribier, 2006) 
The Edwards PHV can be delivered transfemorally or transapically. Transfemoral insertion is a 
process where the Edwards PHV is threaded through the patient’s circulatory system from the leg, as 
shown in Figure 1.14. Transapical insertion, on the other hand, is when it is inserted through the ribs, 
into the apex of the left ventricle and delivered to the site of the patient's native diseased valve, as 
depicted in Figure 1.15.               
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Figure 1.14: Transfemoral/retrograde approach (Webb, 2006) 
 
 
Figure 1.15: Transapical/antegrade approach (Webb, 2006) 
 
Out of 5001 patients, the Euro Heart Survey identified 284 with AS and 216 of those had severe 
AS. Of the patients with symptomatic severe AS, 38% were deemed high risk patients and were refused 
surgery.  These high-risk patients can currently receive balloon valvuloplasty.  However, a study  
3 
 
concluded that 75% of patients having undergone balloon valvuloplasty exhibit hemodynamic evidence 
of restenosis (Lieberman, 1995).  
The CoreValve Revalving System, as shown in Figure 1.16, utilizes an hourglass shaped self-
expanding multi-level nitinol stent, which obviates the need for a balloon (Zajaras & Cribier, 2009).  An 
18 French catheter is used during transfemoral insertion.  The small size of the delivery catheter not only 
improves overall maneuverability but also eliminates the need for surgical access to the femoral artery 
for device insertion.  The bioprostheses is sutured to the nitinol frame, and the valve leaflet pattern and 
attachment geometry are key to the valve’s flow and durability characteristics.     
 
Figure 1.16: CoreValve Revalving System (Cribier, 2006) 
 
The Abiomed Inc. Approach 
 The Abiomed trileaflet polyurethane valve, shown in Figure 1.5, was developed for use in 
ventricular assist devices.  The valve has demonstrated excellent durability and hemocompatibility 
(Rusell, 1980).  Although the valve is commercially available as part of the Abiomed devices, the current 
configuration is not compatible with the requirements of a replacement valve since it is contained 
within a conduit.        
 
Figure 1.17: Trileaflet valve within a conduit (Abiomed Inc.) 
 The polymeric trileaflet valve prosthesis to be modified for transcatheter delivery to the aortic 
position differs from the existing valve in that it has three flexible stent posts. The redesigned valve will 
remain similar to the native aortic valve with three crescent shaped leaflets in a partially opened 
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position as this is a proven design. The contoured leaflets are fabricated from Angioflex®, a proprietary 
polyurethane material, and have a flat free edge and a different thickness distribution compared to the 
existing valve. This new valve seeks to ensure uniform opening and closing characteristics and reduce 
forward flow pressure losses, while simultaneously increasing durability, and minimizing the risks of 
thrombus formation and calcification. To accommodate a range of patients, the outer diameter of 
replacement valves normally range between 19 – 29mm for the aortic prosthesis and 24 – 33mm for 
mitral prosthesis. For the scope of this project, one valve diameter will be developed specifically for 
transcatheter delivery.  The need for a wider range of valve diameters is appreciated and development 
will proceed once the first generation transcatheter valve is successfully developed and demonstrated 
feasible and functionally acceptable. 
The major challenge is the incorporation of the trileaflet valve into a support structure that is 
compatible with incorporation into a delivery catheter similar to the CoreValve Revalving System’s self-
expanding stent. In addition to stent mounting, a means for anchoring the device securely within the 
aortic annulus is of equivalent importance.  Existing stent systems rely on the presence of annular and 
leaflet calcific disease to improve stent stability following deployment. While this will certainly apply for 
the developed polyurethane valve, a reliable anchoring system will have merit should the valve be used 
to treat non-calcific aortic or mitral valve disease. 
 
Project Objectives 
 The objective of this project was the development of a polymeric heart valve that can be 
implanted at low risk using a percutaneous approach, initially for use in patients considered high-risk for 
conventional surgical valve replacement. Pending success in the incorporation of the valve into a low 
profile, efficient and safe delivery system, the valve could have indications for use in a wider range of 
patients with degenerative valvular disease. Key innovations include improved durability and 
hemodynamic properties, lower manufacturing costs, and simplified delivery over existing transcatheter 
bioprosthetic valves.   
 
Scope of Work 
 To prove feasibility of the replacement valve, an iterative approach was observed throughout 
the different stages of the project.  To better define the scope of the assignment, several sub 
components were identified: 
- Use of off-the-shelf stents to allow for rapid attachment mechanism 
- Self-expanding Nitinol stent design 
- Valve attachment to stent 
- Bench-top testing 
- Placement testing 
- In vitro performance evaluation 
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Generic stents were ordered from a Nitinol stent manufacturer and were used to investigate 
several ways to attach a polyurethane valve to a Nitinol frame.  Different stents were designed to enable 
a crimped down size of 18 French and facilitate the attachment process.  These were analyzed for static 
and dynamic structural loading using ANSYS Workbench.  The most viable designs were custom ordered 
and the polyurethane valve leaflet attachments were assessed for forward pressure drop, backflow 
leakage and high cycle failure.  Based on results, the budget allowed for a third round of stents where 
the focus was on delivery and in vitro performance.   
 
Design Requirements 
The design requirements have been defined in collaboration with the project sponsor, Abiomed. 
The following list has been divided into subgroups for ease of navigation. 
Methods/Procedural 
1. The valve must be an acceptable alternative to balloon valvuloplasty for patients who are 
ineligible for surgical valve procedures due to age or comorbidies  
2. A percutaneous valve attachment that is design scalable for range of valve sizes 
o Scalable to accommodate valve sizes from 21 – 24 millimeter   
o 23mm valve leaflets will be attached on a Nitinol stent ranged from 20-24 millimeter 
3. A means of crimping the valve stent to the appropriate size should be optimized 
4. A percutaneous valve attachment method so that when crimped does not jeopardize durability 
or functionality of the valve 
o Valve/Stent system to be implemented into an 18 French (6.0 millimeter) delivery catheter 
5. The method of attachment must be bio/hemocompatible 
6. Should be able to re-ploy stent during initial procedure in case that positioning needs to be 
improved 
o The delivery catheter should support re-deployment of the stent 
7. Extreme aortic stenosis must be considered in the case that radial expansion methods are 
utilized 
8. The valve must be able to be delivered with the apical antegrade approach, and should be able 
to be placed femorally 
Mechanical Strength/Stability 
1. A leaflet/stent attachment method that is proved feasible and durable 
o Design a 3 leaf polyurethane (angioflex) valve to be mounted on a nitnol stent 
o Design an attachment to withstand a 380 million (12 years) cycle life-span or more with 90 
millimeter mercury (mmHg) closing pressures 
o Design an electro-polished stent to keep the Ebd (breakdown potential/corrosion resistance) 
roughly around 800 mV. NOTE: greater than 500 mV is considered anti-corrosive 
2. The valve-stent attachment must reduce shear stress (stress concentration) at commissure and 
attachment points 
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o Wall shear rates must be greater than 10 sec-1, smooth surfaces must be maintained 
throughout Ra less than 0.4 micrometer, step transitions must be less than 100 micrometer 
3. The leaflet folding pattern must reduce the effect of fatigue/creep 
4. The stent and valve attachment must be able to go around the aortic arch 
5. Fixation of the valve to the aortic wall must prevent migration of the valve 
o Want a secure fixation method in the aorta with less than 1 millimeter of displacement with 
closing pressures of 250 mmHg 
Dynamics 
1. A percutaneous valve attachment to improve hemodynamic properties comparable to surgical 
valves 
o The pressure drop should be less than 8 mmHg @ 10 L/m and must be less than 10 mmHg 
o The volume loss closing should be less than 1 milliliter (mL) and must be less than 2 mL 
o The backflow leakage should be less than 5 mL/sec and must be less than 10 mL/sec 
2. A percutaneous valve attachment that does not block any blood pathways nor require any 
anticoagulants 
o Use of anticoagulants such as Coumadin should not be required due to valve/stent 
attachment  
3. Obstruction of the coronary ostia must be avoided 
o An opening in the stent of at least 1 cm2 must exist over each sinus to allow flow into the 
coronary ostia 
4. The valve-stent attachment must reduce thrombus formation 
5. The valve-stent attachment must reduce paravalvular leakage 
6. The valve must be able to be tested with a modified mock loop system already in existence 
7. Obstruction of the aortic nodes must be avoided 
Cost 
1. The method of attachment must reduce manufacturing costs 
o COGS must be less than $500 
2. The valve should be a lower cost alternative to currently available percutaneous tissue valves 
($30-40k selling price) 
 
 
 
 
 
 
  
7 
 
Background Information 
 
Nitinol is an acronym for Nickel Titanium Naval Ordinance Laboratory and it is used to describe a 
family of materials, which contain a nearly equal mixture of nickel and titanium.  The Nitinol alloys were 
originally developed at the Naval Lab and are attractive to the medical device industry because they are 
biocompatible and are at their optimum superelastic behavior at body temperature, when processed 
correctly.   
As a replacement to stainless steel components, Nitinol is often used. A comparison of nominal 
properties between Nitinol and Stainless Steel is provided in the Table 2.1 (Peter & Daniel): 
 
 
Figure 2.1 illustrates the loading and unloading material behavior seen in Shape Memory 
material models when used in their superelastic state. At low levels of stress, the material exists in an 
austenite phase but upon further loading, the material undergoes a stress-induced transformation to a 
martensite phase. The material behaves as linear elastic in both austenite and martensite phases, 
however, the modulus of elasticity in the two phases is different. During the stress induced 
transformation from austenite to martensite there is very little change in stress, but a large increase in 
strain. Beyond the transitions region, the martensite phase ultimately results in permanent 
unrecoverable set in the material. Unloading for cases that do not reach the transformation state follow 
the elastic modulus.  
Table 2.1: Nitinol vs Stainless Steel Properties 
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The superelastic behavior of Nitinol is used in stent design where the transformation 
temperatures are set to be slightly below body temperature. The superelastic effect is caused by the 
stress-induced formation of some martensite above its normal temperature. The martensite reverts 
immediately to un-deformed austenite when the stress is removed. This occurs because it was formed 
above its normal temperature which results in the process providing the elasticity in these alloys for 
strains up to about 8%. 
Nitinol stents have an advantage in that they can be self-deployed. They rely on the 
superelasticity of the material to expand the stent against the artery walls after angioplasty. This 
eliminates the need for balloon expansion and guarantees residual forces between the stent and artery 
wall. 
To help with the design of Nitinol stents, information regarding currently available stents has 
been gathered.  Analyzing and understanding the design considerations that go into making a Nitinol 
stent is a key factor to a successful execution of creating a Nitinol stent that will effectively attach to a 
polyurethane valve. 
 
Survey of Current Stent Designs  
Over 100 different stent designs are currently being marketed or are in evaluation for vascular 
and non-vascular indications. These stents compete for a market that is estimated to be near $3 billion, 
and is expected to double with the advent of drug eluting devices.  A stent design pyramid is presented, 
as seen in Figure 2.2 (Stoeckel, Bonsignore, & Duda, 2002), which breaks the differentiating aspects into 
materials, raw material forms, fabrication methods, geometrical features, and additions. The primary 
distinguishing factor in all groups is balloon-expansion versus self-expandability.  
Figure 2.1: Superelasticity Hysteresis of Nitinol 
(Duerig, Melton, Wayman, & Stockel, 1990)  
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The top of the pyramid and the chosen starting point is the materials used.  This distinguishes 
between balloon expandable and self-expanding stents. From there, the classifications branch out into 
the different forms of materials used, such as sheet, wire or tube and fabrication methods, such as laser-
cutting, waterjet-cutting, and photo-etching.  Next, the vast arrays of geometrical configurations that 
have been explored in stent designs are considered. The classification ends with additions to stents, 
such as grafts, and radiopaque markers and coatings.  
Materials for metallic balloon-expandable or self-expanding stents must exhibit excellent 
corrosion resistance and biocompatibility. They should be adequately radiopaque, and create minimal 
artifacts during MRI.  Balloon-expandable stents are made from materials that can be plastically 
deformed through the inflation of a balloon. After the balloon is deflated, the stent remains in its 
expanded shape, except for a slight recoil caused by the elastic portion of the deformation. The ideal 
material for these stents, therefore, has a low yield stress in order to make it deformable at manageable 
balloon pressures, has high elastic modulus for minimal recoil, and is work hardened through expansion 
for high strength. 
Balloon-expandable stents are manufactured in the ‘small diameter’, that is, deliverable 
configuration, and balloon-dilated to the expanded shape at the target site inside the vessel. Self-
Figure 2.2: Stent Design Pyramid (Stoeckel, 
Bonsignore, & Duda, 2002) 
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expanding stents, on the other hand, are manufactured in the expanded shape, then compressed and 
constrained in a delivery system. Upon release from the delivery system they spring back, that is, self-
expand, to the preset diameter. Their function, therefore, is based on the elastic properties of the 
material used. Ideally, the material should have a low elastic modulus and a high yield stress for large 
elastic strains. Alternatively, the shape memory effect of Nitinol can be utilized. Here, large strains can 
be achieved either superelastically, or via the thermal memory of the material. 
The most widely used self-expanding stent that exhibits large elastic strains is Nitinol, a nickel–
titanium alloy that can recover elastic deformations of up to 10%. This unusually large elastic range is 
the result of a thermo-elastic martensitic transformation. The limited elastic range of more conventional 
materials, such as stainless steel or certain cobalt-based alloys also limits design options. 
Stents can be made from sheet, wire (round or flat) or tubing.  The majority of balloon-
expandable and self-expanding stents are made from wire or tubing.  Figure 2.3 shows an example of 
one made from sheet metal.  Stents made from sheet metal have to be rolled up to a tubular 
configuration after the pattern has been created.   
 
 
 The choice of fabrication method depends mainly on the raw material form used.  Wires can be 
formed into stents in various ways using conventional wire-forming techniques such as coiling, braiding, 
or knitting.  The simplest shape of a wire stent is a coil; all coil stents marketed today are made from 
Nitinol and are self-expanding.  Welding at specific locations after wire forming produces closed-cell 
wire stents or increases longitudinal stability, refer to Figure 2.4.   
 
 
Figure 2.3: Stent Formed From Stainless Steel 
Sheet, Featuring an Axial Backbone with Integral 
Gold Markers (Stoeckel, Bonsignore, & Duda, 2002) 
Figure 2.4: Nitinol Wire Welded to Form a Closed-
Cell Structure (Stoeckel, Bonsignore, & Duda, 2002) 
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The most common wire-based self-expanding stent is a braided design using multiple elgiloy 
(cobalt-based alloys).  This allows continuous production, that is, the stents can be cut to length from a 
long wire-mesh “hose”.  The vast majority of coronary and peripheral vascular stents are produced by 
laser cutting the tubing.  Intricate patterns can be produced using tube sizes from 0.5mm diameter.  
Balloon-expandable stents are cut in the crimped or near crimped condition, and only require post-
cutting deburring and surface treatment, typically electropolishing to achieve adequate levels of 
corrosion resistance.  Self-expanding Nitinol stents can be cut in either the “small” configuration, 
requiring post cutting expansion and shape-setting, or in the expanded condition.  In either case, they 
have to be deburred and polished.   Laser cutting produces a heat-affected zone along the cut edge, 
which has to be removed for better performance.  A cutting method that does not produce a heat-
affected zone is waterjet cutting. A focused jet of water with some abrasive additives is used to cut the 
pattern instead of a laser beam.  Another interesting fabrication method is photochemical etching. 
Although this method is being used to produce stents from tubing, its real benefit is in sheet processing, 
when large numbers of parts can be processed in a single run. 
 Early designs were generally classified as either slotted tube geometries or coil geometries.  
While slotted-tube type designs had excellent radial strength, they lacked stability.  The opposite was 
true of coil designs.  Conflicting design imperatives spawned a rich variety of stent geometries 
competing in a very crowded marketplace, each seeking an optimal balance of strength and flexibility.  
This section classifies stent geometries into five high-level categories: 
1. Coil 
Most common in non-vascular applications, as the coil design allows for retrievability after 
implantation.  These designs are extremely flexible, but their strength is limited and their low expansion 
ratio results in high profile devices. Figure 2.5 shows an example of the “InStent Esophacoil” device. 
 
 
 
2. Helical Spiral 
These designs are generally promoted for their flexibility. With no or minimal internal 
connection points, they are very flexible, but also lack longitudinal support. As such, they can be subject 
to elongation or compression during delivery and deployment and, consequently, irregular cell size. 
With internal connection points, some flexibility is sacrificed in exchange for longitudinal stability and 
additional control over cell size. The Crossflex stent depicted in Figure 2.6 is an example of a minimally 
connected helical spiral geometry. 
Figure 2.5: Coil Stent Fabricated from Nitinol Ribbon 
(Stoeckel, Bonsignore, & Duda, 2002) 
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3. Woven 
This category includes a variety of designs constructed from one or more strands of wire. 
Braided designs are often used for self-expanding structures. While these designs offer excellent 
coverage, they typically shorten substantially during expansion. The radial strength of such a braided 
structure is also highly dependent on axial fixation of its ends. The Strecker stent (Figure 2.7) is an 
example of a balloon-expandable knitted tantalum stent, while the Cook ZA (Figure XX) stent 
demonstrates a self-expanding knitted Nitinol wire design.  
  
 
 
 
 
4. Individual Rings 
Single “Z”-shaped rings are commonly used to supports grafts or similar prostheses. They can be 
individually sutured or otherwise attached to the graft material during manufacture.  These structures 
are not typically used alone as vascular stents.   
Figure 2.6: Crossflex – A Minimally Connected Helical Spiral Stent Fabricated from 
Stainless-Steel Wire (Stoeckel, Bonsignore, & Duda, 2002) 
Figure 2.7: Strecker Stent Made of Knitted Tantalum Wire 
(Stoeckel, Bonsignore, & Duda, 2002) 
Figure 2.8: Cook ZA-Knitted Nitinol Wire Design, Featuring Sleeve-Type Gold 
Markers (Stoeckel, Bonsignore, & Duda, 2002) 
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5. Sequential Rings  
This category describes stents comprised of a series of expandable Z-shaped structural elements 
(known as ‘struts’) joined by connecting elements (known as ‘bridges’, ‘hinges’, or ‘nodes’). This type of 
construction accounts for the majority of commercially available stents.  Regular connection describes 
bridging elements that include connections to every inflection point around the circumference of a 
structural member. Periodic connection describes bridging elements that include connections to a 
subset of the inflection points around the circumference of a structural member. Connected inflection 
points alternate with unconnected inflection points in some defined pattern.  “Peak–peak connection” 
or “peak–valley connection” are terms used to describe the locations at which the bridging elements 
join adjacent structural members. “Peak–peak” bridging elements join the outer radii, and “peak–valley” 
bridging elements join outer radii to inner radii of the inflection points of adjacent structural members. 
Closed Cell describes sequential ring construction wherein all internal inflection points of the 
structural members are connected by bridging elements. Such a condition is typically only possible with 
regular peak-to-peak connections. Early slotted-tube type designs, such as the Palmaz stent (Figure 2.9), 
were strong, but inflexible.  
 
 
Later designs, such as the NIR stent (Figure 2.10), improved upon this concept by adding a flex 
connector. These U-, V-, S-, or N-shaped elements plastically deform during bending, allowing adjacent 
structural members to separate or nest together, to more easily accommodate changes in shape. The 
primary advantages of closed-cell designs are optimal scaffolding and a uniform surface, regardless of 
the degree of bending. However, these advantages result in a structure that is typically less flexible than 
a similar open-cell design. 
 
 
Figure 2.9: Palmaz-Schatz Stent, Each Half Represents a Closed Cell Slotted Tube Structure 
Figure 2.10: NIR stent, a closed-cell structure featuring “V” flex hinges 
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Open Cell describes construction wherein some or all the internal inflection points of the 
structural members are not connected by bridging elements. This allows periodic peak-to-peak 
connections, peak-to-valley connections, and mid-strut to mid-strut connections, as well as innumerable 
hybrid combinations. In open-cell designs, the unconnected structural elements contribute to 
longitudinal flexibility.  Periodically connected peak-to-peak designs are common among self-expanding 
stents, such as the SMART stent (Figure 2.11), as well as balloon-expandable stents, such as the AVE S7 
(Figure 2.12). 
 
 
 
 
The peak-to-valley connection of the ACS Multilink (Figure 2.13) virtually eliminates 
foreshortening and assures that adjacent structural peaks are aligned peak-to-valley throughout the 
expansion range of the stent, optimizing scaffolding characteristics. However, the peak-to-valley 
connectors take up material that could otherwise be used for structural members. Consequently, 
structures with this type of peak-valley connection are generally not as strong as similar structures with 
peak-to-peak connections.  While these peak-to-peak and peak-to-valley connections are most common, 
there are also examples of other variations, such as the BeStent (Figure 2.14).  
Figure 2.11: SMART Stent – Self-Expanding Open 
Cell Sequential Ring Design with Periodic Peak-to-
Peak Non-flex Connectors 
Figure 2.12: AVE S7 Stent – Balloon Expandable 
Open-Cell Sequential Ring Design with Periodic 
Peak-to-Peak Non-flex Connectors 
15 
 
 
 
 
 
More than 100 different stent designs exist today because this development has been mainly 
driven by patent and marketing issues rather than actual scientific considerations.   However, that many 
brands are not needed.  Therefore, there are currently solid investigations underway testing 
biocompatibility, potentiodynamic polarization, corrosion resistance, thrombogenicity, radiopacity, 
chronic fatigue behavior in addition to more classic properties like flexibility, trackability and sheaf 
compatibility.  
Appendix A presents a table of the most commonly known stents along with their fabrication methods 
and comments.  Pictures for some of the stents can also be found in the aforementioned section. 
 
Nitinol Stents - Material and Design Considerations 
Conventional stent materials, like stainless steel or cobalt based alloys, exhibit a distinctly 
different elastic deformation behavior from that of the structural materials of the living body. The elastic 
deformation of these metals and alloys is limited to approximately 1% strain, and elongation typically 
increases and decreases linearly with the applied force. In contrast, natural materials, like hair, tendon 
and bone can be elastically deformed, in some cases, up to 10% strain in a non-linear way (S, 1996). 
Figure 2.13: ACS Multilink – Balloon Expandable 
Open-Cell Sequential Ring Design, with Peak-to-
Valley Connections 
Figure 2.14: BeStent – Balloon Expandable Open-
Cell Sequential Ring Design, with Midstrut-to-
Midstrut Connections and Integral Gold Markers 
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When the deforming stress is released, the strain is recovered at lower stresses. As shown in Figure 
2.15, the loading/unloading cycle is characterized by a pronounced hysteresis.  
 
 
A similar behavior is found with Nitinol alloys. As with natural materials, the loading and 
unloading curves show plateaus, along which large strains can be accumulated on loading, or recovered 
on unloading, without significant increase, or decrease, respectively, in stress. The schematic stress-
strain diagram for Nitinol at body temperature and that of stainless steel is shown in Figure 2.16.  
Deformation of more than 10% strain can be elastically recovered. 
 
 
Superelastic Nitinol appears macroscopically to be simply very elastic. However, the mechanism 
of deformation is quite different from conventional elasticity, or simply stretching of atomic bonds. After 
a rather modest elastic deformation, when a stress is applied to Nitinol, the material yields to the 
applied stress by changing its crystal structure. This stress induced phase transformation allows the 
material to change shape as a direct response to the applied stress. When the stresses are removed, the 
material reverts to the original structure and recovers its original shape. While superelasticity is the 
result of a stress induced phase transformation, shape memory is the result of a thermal phase 
transformation. In fact, the superelastic Nitinol also changes its crystal structure when it is cooled to 
below a critical temperature, the transformation temperature, which is dependent on alloy composition 
and processing history. If no force is applied, this phase change is not accompanied by a shape change. 
Figure 2.15: Deformation Characteristics of NiTi and Living Tissues (Stoeckel, 
Pelton, & Duerig, 2003) 
Figure 2.16: Stress-Strain Diagram for Nitinol and 
Stainless Steel (Stoeckel, Pelton, & Duerig, 2003) 
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The material can be plastically deformed in the low temperature phase but the original shape can be 
restored by heating above the transformation temperature (Duerig, Melton, Wayman, & Stockel, 1990). 
Self-expanding Nitinol stents are manufactured with a diameter larger than that of the target 
vessel. Their transformation temperature is typically set to 30oC. They can be easily crimped at or below 
room temperature and placed in a delivery system. To prevent premature expansion during delivery into 
the body, the stent is constrained by a retractable sheath or other means. At the treatment site it is 
released from the delivery system and expands until it hits the vessel wall and conforms to it. Now at 
body temperature, the stent is superelastic. 
Nitinol has found widespread acceptance as a material of choice for medical implants and 
devices (Stoeckel D. , 2000).  It derives its unique properties from a solid state transformation which may 
be triggered thermally or mechanically, which adds another level of complexity to the material 
specification.  On top of the commonly known material characteristics such as chemical composition, 
Young’s Modulus, yield strength, ultimate tensile strength and elongation to failure, properties like 
transformation temperature, upper and lower plateau stress, recoverable strain and permanent set 
have to be taken into account.  These properties are strongly dependent on the processing history and 
play an important role in the design and manufacturing of self-expanding stents.   
Nitinol requires controlled processing to achieve optimal shape memory and superelastic 
properties (Pelton, DiCello, & Miyazaki, 2000) and properly treated Nitinol implants are very corrosion 
resistant and biocompatible (Wever, Veldhuizen, Sanders, & Schakenraad, 1997). Just like titanium and 
stainless steel, Nitinol forms a stable surface oxide layer that protects the base material from general 
corrosion (Wever D. e., 1998). Considering the high nickel content of the alloy, there are concerns that 
nickel may dissolve from the material due to corrosion and cause adverse effects. On the other hand, 
other alloys that contain high levels of nickel, such as MP35N (a Co alloy with 35 weight % Ni), or 300 
series stainless steel (approx. 10 weight % Ni) exhibit good biocompatibility, and have long been used as 
implants in orthodontics, orthopedics and cardiovascular applications (Brown, Hughes, & Merritt, 1988).  
Several studies have measured nickel release during the exposure of Nitinol implants to body fluids. 
During an in vitro dissolution study of Nitinol dental archwires in saliva (Barrett, Bishara, & Quinn, 1993), 
it was found that Nitinol appliances released an average of 13.05 mg/day nickel, which is significantly 
below the estimated average dietary intake of 200-300 mg/day.  
To evaluate the effect of different surface treatment methods on the Ni-ion release, Trepanier 
et al (Trepanier, Venugopolan, Messer, Zimmerman, & Pelton, 2000) immersed mechanically polished 
and electro-polished samples of Nitinol, MP35N and 316L stainless steel in saline solution at 37oC for a 
period of greater than 1000 hours.  It was found that samples that were prepared by mechanical 
polishing released higher amounts of Ni-ions than those prepared by electropolishing. Surface analysis 
data demonstrated that the electropolishing process removes excess nickel from the surface and forms 
a layer enriched in titanium (in the form ofTi02).  In contrast, the mechanically polished samples have a 
relatively high concentration of nickel in the surface. Furthermore, the mechanically polished Nitinol and 
MP35N samples show an increase in Ni ion release after 1000 hours. This may be due to corrosion 
activity (pitting) after the initial 1000 hour time period in the non-passivated samples.   
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ASTM standard F2129 provides a quantitative method recognized by the FDA for the accelerated 
assessment of the corrosion resistance of implant materials (F2129-01, 2002). The most relevant data 
derived from this test is the break-down potential Ebd since most biomaterials corrode locally by pit 
formation. A high breakdown potential indicates that the material is very stable and resists pitting. 
Although no official limits have been established, materials with an Ebd ≥ 500 mV are considered 
sufficiently corrosion resistant and safe for the use as implants. 
Anodic polarization tests per ASTM F2129 have been used to evaluate the influence of surface 
preparation on the corrosion susceptibility of Nitinol stents. Trepanier at al. (F2129-01, 2002) have 
shown that electro-polished Nitinol stents have excellent corrosion resistance with breakdown 
potentials greater than 800 mV, whereas the Ebd of non-electro-polished stents was on the order of 200 
mV. It was further shown that the breakdown potential of electro-polished stents was degraded to less 
than 500 mV after thermal treatments in the 400oC to 500oC range. This led to the conclusion that 
optimal corrosion and biocompatibility results are obtained with a thin, titanium oxide (TiO2) surface 
layer formed after electropolishing (passivation) treatments. It further appears that uniformity, rather 
than thickness, of the oxide is most important to protect the material from corrosion.   
In 1999, the medical community and the device industry were alerted to the corrosion issue by 
reports by Riepe et al (Heintz, et al., 2001) on the observation of severely corroded Nitinol graft 
scaffolds from explanted Stentor aortic stent grafts after five months implantation (Figure 2.17). It was 
preliminarily speculated that cell-induced electrochemical corrosion or active cellular destruction of the 
surfaces might have been responsible for the severe corrosion. However, subsequent cell culture testing 
with Nitinol test samples performed by Riepe’s group did not induce any corrosion (E, 2002). Further 
analysis of the failed components revealed an oxide thickness of 0.2-0.3 µm (determined by Auger 
analysis) and an Ebd of 280 mV (from anodic polarization tests). In contrast, 12 month explants of 
electro-polished graft scaffolds examined by Pelton et al showed no signs of corrosion. The oxide 
thickness on these devices was approximately 0.01 µm and the Ebd > 900 mV. This highlights the 
importance of optimized surface preparation. Most Nitinol stents marketed today have electro-polished 
surfaces. 
 
 
Figure 2.17: Top – Heavily Corroded NiTi Explant; Bottom – 
Electro-Polished NiTi Explant (Brown, Hughes, & Merritt, 1988)  
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The most unusual property of Nitinol alloys is stress hysteresis. While in most engineering 
materials stress increases linearly with strain upon loading and decreases along the same path upon 
unloading, Nitinol exhibits a distinctly different behavior. After an initial linear increase in stress with 
strain, large strains can be obtained with only a small further stress increase. This is called the loading 
plateau.  The end of this plateau is reached at about 8% strain. Unloading from the end of the plateau 
region, causes the stress to decrease rapidly until a lower plateau (unloading plateau) is reached. Strain 
is recovered in this region with only a small decrease in stress. The last portion of the deforming strain is 
finally recovered in a linear fashion. 
The stress hysteresis or path dependence of Nitinol results in a device feature termed biased 
stiffness (Duerig, Pelton, & Stoeckel, The use of Superelasticity in Medicine, 1996). This concept is 
illustrated in Figure 2.18, which shows a schematic superelastic stress-strain curve for Nitinol, 
demonstrating both non-linear response and hysteresis. Using this graph, the cycle of crimping a stent 
into a delivery system, deploying it and have it expand and interact with the vessel will be followed. For 
this purpose, the axes have been changed from stress vs. strain to hoop force vs. stent diameter. A stent 
of a given size larger than the vessel (point a) is crimped into a delivery system (point b). After insertion 
to the target site, the stent is released into a vessel, expanding from b until movement is stopped by 
impingement with the vessel (point c). At this point, further expansion of the stent is prevented. 
Because the stent did not expand to its pre-set shape, it continues to exert a low outward force, termed 
chronic outward force or COF.  However, it will resist recoil pressures or any other external compression 
forces with forces dictated by the loading curve from point c to d, which is substantially steeper (stiffer) 
than the unloading line (towards e). These forces are called radial resistive forces or RRF. 
 
 
Another unusual feature of Nitinol stents is their temperature dependent stiffness. Stents with a 
transition temperature of 30 degrees Celsius feel quite weak when squeezed or crushed at room or 
lower temperature. In contrast, they feel much stiffer when squeezed at temperatures above 30 
degrees. Figure 2.19 shows actual unloading curves of a Nitinol stent (Cordis SMART Stent) with a 
diameter of 10 mm at different temperatures. The test setup is described in (Duda, et al., 2000). As can 
Figure 2.18: Stress Hysteresis and Biased Stiffness 
(Stoeckel, Pelton, & Duerig, 2003) 
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be seen from this graph, the chronic outward force actually doubles when the temperature is increased 
from 20 to 37 degrees Celsius. The transition temperature of the stent can be adjusted to a certain 
extent during processing, which gives the designer another option to increase or decrease the radial 
forces of the stent without changing the design or physical dimensions. For each degree that the 
transition temperature is below body temperature, the loading and unloading forces increase by 
approximately 4 N/mm2. 
 
 
Kink resistance is an important feature of Nitinol for stents in superficial vessels that could be 
deformed through outside forces. The carotid artery is a prime example. There is a perceived risk for 
balloon-expandable stents in carotid arteries to be permanently deformed through outside pressure 
resulting in a partially or completely blocked vessel once the buckling strength of the stent is exceeded. 
Although Nitinol stents typically do not have the buckling strength of stainless steel stents, they cannot 
be permanently deformed through outside forces. Nitinol stents can be completely compressed flat and 
will return to their original diameter when the deforming force is removed (Figure 2.20).  
 
  
Figure 2.19: Unloading Curves of Nitinol Stents at Different 
Deployment Temperatures (Stoeckel, Pelton, & Duerig, 2003) 
Figure 2.20: Extreme Deformation of a NiTi Stent 
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Basics of Nitinol Stent Design 
 Despite the information gathered on the currently available stents and the design and material 
considerations involved in designing a stent, the team was still lacking direction as to how to model the 
stent.  It was understood that transformation temperature plays in role in the COF and RRF and that 
electropolishing is important for corrosion resistance.  However, there is little background as to how the 
stent geometry affects performance.  Figure 2.21 shows a 3D model generated in SolidWorks with the 
different parameters that make up the stent geometry. 
 
 
 
 To gather more information about the specifics of designing a stent, Abiomed Inc. hired a Nitinol 
consultant to present a Basics of Stent Design seminar.  The consultant was referred to the team by 
Admedes, a stent manufacturer, with which the team worked closely during the course of this project.  
The reader must keep in mind that the information presented in this section represents the 
team’s understanding and interpretation of the information provided during the seminar.  Since Nitinol 
is a very novel material in the medical industry, most information available is based on experience 
rather than hard facts.   The most relevant design criteria covered during the presentation are listed 
below: 
Figure 2.21: Stent Geometry 
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- Crossing Profile 
The crossing profile is the diameter of the starting raw tube size.  For any percutaneous valve, 
the outside diameter of the delivery system defines the size of the stent.  Most valves currently on the 
market have an 18 French (6.00 mm) diameter.  For a valve to be crimped down to an 18 French 
diameter, it is advised to start with a 16 French starting raw tube size. 
- Over-sizing 
Over-sizing the stent for anchoring is very common.  Looking at the stress-strain diagram and 
taking into account the high RRF and low COF, over-sizing does present a sound means of anchoring the 
valve to the aortic annulus.  Moreover, calcification of the aortic valve renders the tissue around the 
replacement valve stiffer and reduces the risk of tissue relaxation and migration of the stent.  These are 
however, only theoretical assumptions that haven’t been validated.  Other means of anchoring should 
be explored.  Using surface finishes that promote tissue growth, stents with more apexes and flared 
ends stents are options that should be considered when trying to improve anchoring. 
- AF temperature 
The AF temperature is the transformation temperature that was described in earlier sections.  
The AF temperature is specified to the stent manufacturer and typically should be higher than room 
temperature (23oC) but lower than body temperature (37oC).   
- Foreshortening 
When the stent is crimped down, its height increases and it becomes shorter during radial 
expansion. This is an important consideration when designing a stent as the peak-to-peak or peak-to-
valley connectors need to have the ability to elongate or shorten.  An example of a viable connector is 
shown in Figure 2.22.  
 
 
- Radial Strength 
As discussed in earlier sections, the radial strength of the Nitinol stent was covered during the 
presentation.  The information provided was in line with the literature review conducted and will not be 
presented again. 
Figure 2.22: Peak-to-Peak Connector 
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- Flexibility 
Depending on the insertion method (femoral or apical), the stent needs to have a certain degree 
of flexibility.  For an open cell stent, the flexibility can be adjusted by the addition of flex connectors.  
For apical insertion, where the stent is introduced through the rib cage and delivered in a straight line, 
the stent can be more radially stiff.  However, for femoral insertion, where the stent has to go around 
the aortic bend, the stent needs to be more flexible.  
 
 
- Strain 
A self-expanding Nitinol stent will experience two major types of strains during its lifetime.  The 
first type of strain is during the crimp down phase before insertion into the delivery system.  From 
experience, it was recommended to the team that the strain endured during this process be no more 
than 6-8% of the ultimate tensile strength (Sut) of the stent.  The second occurs throughout the lifetime 
of the stent, while it is in use within the aortic valve.  It experiences a pulsatile step with each heart beat 
and due to the fatigue nature of the loading, the alternating strain should be kept under 0.4% of the Sut. 
- Strut Width 
Once again, due to the lack of hard evidence, the team has to rely on the consultant’s 
experience.  The ratio of width to wall thickness was recommended to be 1 to 1.5 to avoid out-of-plane 
deformation.  Figure 2.24 shows a schematic of the strut width and wall thickness.  
 
 
- Apex Geometry 
The ratio of apex width to strut width should be roughly 1 to 1.3 to have an optimum strain 
distribution over the apex area.  “Overloop” sometimes occurs during crimping and is a result of the gap 
being too small.  Overloop is the overlapping of two adjacent struts connected by the same apex.  
Figure 2.23: Flex Connector in an Open Cell Stent 
Figure 2.24: Strut Width and Wall Thickness 
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Increasing the gap and introducing a “keyhole” feature also help in reducing strain.  Figure 2.25 provides 
a drawing of the apex geometry and Figure 2.26 shows a keyhole feature meshed for finite element 
analysis.       The stent designer needs to be careful when increasing the gap size.  Too much gap can 
cause a “train wreck” failure.  A “train wreck” failure happens when the apexes deform past what was 
accounted for by the engineer and effectively buckles.   
 
 
 
 
 
- Apex/Strut Angle 
The apex angle should be kept under 90 degrees.  Apex angles over 90 degrees decrease the 
stability of the structure and can lead to crimping issues.  They also induce high strains which have 
caused cracks during shape setting, even with annealing of the stents in between each incremental heat 
set.  Shape setting is discussed in more detail later in this section. 
- Strut Length 
A short strut length enhances flexibility of the stent due to the presence of less material.  A 
shorter strut means that the stent needs more struts and therefore more apexes.  They add to the radial 
strength of the stent.  A longer strut increases the stress/strain resistance of the stent due to the 
amount of material present. 
- Stent Manufacturing 
Each stent manufacturer has its own proprietary technique for manufacturing stents but they 
usually consist of the following six steps.  Stent designers have little control over these steps as they only 
Figure 2.25: Apex Geometry 
Figure 2.26: “Keyhole” Feature 
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reflect what the stent manufacturer has to offer.  It is however, good background for the reader who 
seeks to learn more about state-of-the-art Nitinol stent manufacturing.   
1. Laser cutting: Stent manufacturers usually know the design intent but there is a lead in and 
lead out mark that is caused by the point of entry of the laser and its point of exit.  While 
this consideration is beyond the scope of this project, later stages of stent design need to 
consult with the manufacturer as to where these marks are located on the stent.   
2. Cleaning: Once the raw tubing is cut, it is cleaned.  The individual process used by each 
company was not disclosed to the design team.  The design team anticipates the use special 
solutions in ultrasonic baths to that end.   
3. Shape-setting/Thermal Processing:  To increase the diameter of the tube from the raw 
starting size to that of the final stent, incremental steps are used.  After each heat set, the 
stent is annealed to prevent formation of micro-cracks and prepare it for the next heat set.  
This thermal processing is also responsible for setting the AF temperature of the stent. 
4. Oxide removal: During heat set, heavy layers of TiO2 are formed.  A TiO2 layer is beneficial for 
corrosion resistance but an electro-polished stent provides more corrosion resistance at a 
reduced thickness. Since stent profile is very important, the stent is usually sand-blasted or 
chemically etched to remove the layer of TiO2.     
5. Electro-polishing: As mentioned, electro polishing increases corrosion resistance.  Some 
companies use a methanol-based electrolyte but electro-polishing removes material at the 
apexes at a greater rate than along the struts, as shown in Figure 2.27.  That is one of the 
reasons why a ratio of 1 to 1.3 should be respected for strut width to apex width.  
6. Passivation:  Once again, the design team does not have much information regarding the 
passivation process but as discussed earlier, it improves corrosion resistance. 
 
 
 
- Testing 
Different test methods were discussed during the presentation but since Abiomed Inc. does not 
possess any of the test equipment and the design team did not account for additional testing in the 
budget, a discussion of the test setups was omitted in this section.   
Figure 2.27: Extreme Deformation of a NiTi Stent 
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FEM of Nitinol Stents 
The superelasticity, which results in an order of magnitude increase in recoverable strain, is one 
of the most attractive assets of Nitinol. Finite element modeling has been used for many years as a 
predictive tool for capturing the stress and strain response of metallic structures. Isotropic and 
Kinematic plasticity laws have allowed analyst to predict the response of steels well beyond their initial 
yield point. Material laws have also been able to capture the hysteretic behavior using material laws 
such as the rate-independent nonlinear kinematic hardening model (Chaboche J. L., 1989) (Chaboche J. , 
1991) to simulate the ratcheting response under cyclic loading. These material laws however cannot 
capture the unique loading and unloading response of Nitinol. In order to simulate the unique cyclic 
structural response of Nitinol products, a new material model is required. 
While there are numerous FEM programs on the market, ANSYS was selected as the most 
appropriate one for the purpose of this project.  Abiomed Inc. has licensing rights to ANSYS only and any 
work undertaken for this project must be compatible with the software available at the sponsor.  
Moreover, the literature review has indicated that ANSYS has the most user friendly interface to create 
a material model that can accurately mimic the behavior of shape memory alloys.      
Analytical material models currently used to evaluate the response of metallic parts in ANSYS 
are inadequate to characterize the unique hysteretic behavior of Shape Memory Alloys such as Nitinol. 
In traditional plasticity laws, the unloading behavior of the material follows the elastic modulus slope. 
With Nitinol the behavior follows a hysteresis where the unloading curve follows neither the non-linear 
loading nor elastic modulus unloading curves. 
During the development of a new material model, a one element problem is usually sufficient to 
test the initial implementation of the constitute model. The Nitinol material model undergoes large 
strain behavior that can be tested by performing a displacement controlled solution simulating a uniaxial 
stress and strain state. By comparing the input with the computed stress and strain state, checking of 
the correct implementation of the material model is obtained. 
 
 
Figure 2.28: Single Element Test Model (Peter & 
Daniel) 
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Figure 2.28 illustrates the one element model used in the testing of the Nitinol material model. 
Symmetry boundary conditions were used on all faces to create a uniaxial stress state. Checking of the 
stress state in all directions was used to indicate proper implementation. Figure 2.29 illustrates a history 
plot of the material model input vs. the calculated stress vs. strain response. Note that a number of runs 
are superimposed where different levels of hysteretic behavior are modeled. Strain levels of 2% - 7% are 
included in both loading and unloading curves. The hysteretic behavior is clearly seen in these curves. 
The data extracted from the time history postprocessor matches within acceptable error the material 
properties input into ANSYS. By using a single element model, testing of highly nonlinear analyses can be 
performed in seconds. Although this analysis does not guarantee an acceptable model has been 
achieved, it is the first step in the verification process. 
 
 
The following analysis procedure is used to characterize the response of Nitinol Stents. The 
loading procedure consists of the typical steps performed in the design of Nitinol stents: 
1. The Laser-cut polished stress free geometry is the starting point of the analyses. Often this is 
provided to the engineer in the form of a 2D drawing, where a geometry transformation is 
necessary to generate a 3D model of the smallest repeatable segment. Figure 2.30 
illustrates the results of extruding the given 2D geometry into a flat 3D meshed repeatable 
segment of the device followed by a coordinate transformation from Cartesian to Cylindrical 
to create the 3D model.  
Figure 2.29: Single Element Uniaxial Stress-Strain Response 
(Peter & Daniel) 
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2. The stent is next compressed onto the delivery device, which is typically at a similar 
diameter to the original tubing. A “rigid” cylinder contact surface is used for this stage of the 
analysis process. (Figure 5)  
 
 
3. Releasing the stent from the delivery device simulates deployment. In the finite element 
model enlarging the “rigid” cylinder to the vessel diameter can simulate this deployment.  
  
Figure 2.30: Stent Analysis Steps Conclusion 
(Peter & Daniel) 
Figure 2.31: Stent Analysis Steps 
(Peter & Daniel) 
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Abiomed Inc. Polyurethane Valve 
 Abiomed Inc. has developed a polyurethane valve platform technology, which has performed 
well in the BVS 5000, a ventricular assist device developed and commercialized by Abiomed Inc. (Jett, 
1996).  To ensure unidirectional flow, the Abiomed BVS 5000 makes use of two 25mm trileaflet (Figure 
2.32) polyurethane valves fabricated from AngioflexTM (Renè, Daniel, & Gregory, 2001).  After the 
success of this valve, Abiomed Inc. developed a surgical version of this valve which is currently used for 
surgical valve replacement procedures.  The surgical valve is based on the same trileaflet pattern 
attached to the commissures.  The surgical version however, features a velour sewing cuff as shown in 
Figure 2.33.      
 
 
 
 
 As mentioned in earlier sections, the medical device industry, including Abiomed Inc., soon 
realized the need for percutaneous valves.  Since it had experienced success with its polyurethane valve, 
Abiomed decided to attempt to create a percutaneous version of the valve and attach it to a stent.  For 
the very first iteration, a piece of plastic tubing was cut into the shape of a stent and the percutaneous 
version of the polyurethane valve was attached as proof of concept.  The resulting valve and stent 
assembly is shown in Figure 2.34.   
Figure 2.32: Trileaflet valve used in BVS 5000 
Figure 2.33: Abiomed Surgical Valve 
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Benefits 
 The Abiomed Polyurethane valve is believed to be superior to tissue valves and mechanical 
valves for the reasons listed below.  These reasons were not investigated by the design team as it was 
outside the scope of the project to identify superiority of the polyurethane valve.  The reader needs to 
understand that the reasons listed below were accepted by the design team based on good engineering 
judgment as opposed to facts backed by testing. 
 As opposed to a polymeric valve, 
1. A tissue valve is more likely to be affected by calcification. 
2. Tissue valves can only be sutured onto the stent.  Several attachment techniques are plausible 
with a polyurethane valve. 
3. The thickness of a tissue valve leaflet cannot be varied during manufacture. 
4. A mechanical valve requires the patient to be on blood thinners. 
5. Tissue valves are not reproducible; each one is unique and will have slightly different properties. 
Manufacture 
 Abiomed’s standard dip casting process is used with stainless steel mandrels to build the valve 
leaflets and mounting geometry. The mandrels are dipped into a proprietary, highly purified 
polyurethane (AngioflexTM) solution, followed by evaporation curing. During evaporation curing, the 
mandrels are rotated at a constant speed to achieve a uniform valve leaflet thickness.  Figure 2.35 and 
2.36 show mandrel in the dipping position and the mandrel fully submerged respectively.   
Figure 2.34: Abiomed 1st Valve and Stent Assembly 
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Attachment 
 Unlike tissue valves, there are numerous ways that a polyurethane valve can be attached to a 
Nitinol stent.  The four methods that the design team is considering are: 
1. Dip casting 
2. Solvent Bonding 
3. Suturing 
4. Thermoforming 
Figure 2.35: Mandrel in Dipping Position 
Figure 2.36: Fully Submerged Mandrel 
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These attachment techniques will be explained in more detail under the Methodology section.  
The design team will attempt to perform all these attachment techniques except for suturing.  Abiomed 
Inc. has clean room operators who currently perform suturing operations for other products and 
possess significantly more experience.  Dip casting, solvent bonding and thermoforming are very 
convenient techniques as the attachment can be dissolved in solvent.  In other words, should the 
attachment of the valve leaflet to the stent not be as desired, the stent can be placed in solvent which 
will dissolve all the polymeric materials present, leaving a brand new stent behind.  Since manufacturing 
new valves can be done overnight, this feature will certainly prove to be very convenient. 
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Methodology 
Evaluation of Generic Stents 
 Prior to the approval of this project, the project lead, S. Corbett met with representatives of 
Admedes GmbH and they drafted three generic stent iterations that Abiomed Inc. could use in its future 
endeavor of designing a percutaneous valve.  For the first and second iterations, the only information 
that was provided was the 23mm diameter of the valve that the stent had to hold.  (Note: Appendix B of 
this report shows a schematic of a French catheter scale for easy conversion between metric and French 
scales.)  The third iteration had to follow the contours of the valve leaflet for added support.  S. Corbett 
quickly drafted the valve leaflet pattern on a piece of napkin at the lunch meet.  Admedes GmbH 
created three versions of stents based on these two requirements and delivered them to Abiomed Inc.  
These stents are shown in Figure 3.1 - 3.3. 
 
 
 
 
 
Figure 3.1: Generic Curved after dip casting leaflet 
Figure 3.2: Generic Straight 
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 A visual inspection of the stents revealed that the Generic Straight had 18 apexes, the Generic 
Curve had 12 and the Generic Crown had a total of 36 apexes.  Squeezing the stents with the thumb and 
first finger confirmed the theory that the number of apexes is directly related to the radial stiffness of 
the stent.    
 The strut thickness of each stent was measured with a calibrated micrometer.  The micrometer 
used was a Mitutoyo Spherical Face Micrometer Series 395-251. Figure 3.4 shows a picture of the 
micrometer used.   10 readings were taken at different places on each stent and the average values for 
each was calculated.  Appendix C displays the 10 individual readings used to obtain the average values:  
Generic Straight: 0.63mm 
Generic Curved: 0.47mm 
Generic Crown: 0.56mm     
 
 
 The Spherical Face Micrometer was used as it is specifically designed to measure tube thickness.  
It decreases contact area significantly and unlike regular flat faced micrometers, the Spherical Face 
causes less deflection when applying pressure on the struts.  Precision instruments such as the Mitutoyo 
Micrometer get calibrated on a regular basis at Abiomed Inc. and the device had been calibrated within 
the past 6 months. 
Figure 3.3: Generic Crown after dip casting valve leaflet 
Figure 3.4: Spherical Face Micrometer (Mitutoyo) 
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 To take thickness measurements, the desired area was clamped with the micrometer prongs 
very gently.  Instead of using the ratchet, the micrometer would be lifted up until the stent would not be 
in contact with the work space anymore.  The prongs were adjusted so that they would only barely hold 
the stent when lifted off the table by the micrometer.  This method assured that no excessive pressure 
was exerted on the strut and that accurate readings were being monitored.   
 A set of calipers were used to obtain the diameter of the stents.  The same approach was used 
to avoid stent deformation and ensure accurate data capture.  All three were found to have diameters 
very close to 23mm.  Appendix C of this report shows the exact diameter measurements for each stent.     
 The next step was to try and crimp down the stent to its minimum diameter size.  The previous 
monitoring tests were performed before crimping down the stent in case the stents experienced 
permanent deformation or strut fracture was observed.  To identify the minimum crimp down size of 
the stents, they were forced into an off the shelf funnel with a minimum 18 French diameter size bore.  
A 150mm long, 30mm diameter delrin rod with a circular groove was used to push the stents into the 
plastic funnel.  Delrin was chosen as it is easy to machine and it is a readily available scrap part at 
Abiomed Inc.  The design team ensured that the diameter of the rod was slightly bigger than the size of 
the stents.  The circular groove had a 23mm diameter, and a 2mm depth.  It was machined using a 1/8” 
(3.175mm) drill bit. The edges were then deburred to obtain a fillet of roughly 0.1mm.  A 3D model of 
the Delrin Push Rod with the aforementioned features is shown in Figure 3.5. 
 
 
Using the Delrin Push Rod, the Generic Curved stent would buckle and the Generic Crown and 
Generic Straight stents would simply refuse to go into the funnel.  A second approach was to pull the 
stents into the funnel instead of pushing them into the decreasing radius.  To that end, threads were 
tied to three equidistant apexes of each stent and they were pulled into the funnel.  Once more the 
Figure 3.5: 3D model of Delrin Push Rod 
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Generic Crown and Generic Straight stent did not go into the funnel significantly but the Generic Curved 
stent was successfully crimped down to the minimum diameter of the funnel, that is, 18 French.   
After it was demonstrated that the Generic Curved stent could be crimped into the funnel, it 
was inserted through a tube with an 8mm (24 French) inner diameter using the threads and funnel 
approach.  As shown by Figure 3.6, when the Generic Curved Stent was placed into the tube, the 
polyurethane valve had been thermoformed onto the stent.  The polyurethane valve was added to 
investigate the struts’ behavior under compression while being attached to the valve.  The side-view of 
the collapsed stent (Figure 3.7) shows a very uneven strut deformation.  From this picture, it can be 
concluded that the pressure distribution when the stent is crimped down is non-even and particular 
struts are experiencing more stress and are more likely to fail.     
 
 
 
 
 
 To investigate whether the uneven strut deformation was due to the unorthodox crimp down 
mechanism currently being utilized or the valve attachment, a stent crimper was purchased.  Using a 
certified stent crimper would remove this unknown factor and help the design team converge on a root 
cause.  From talking to more experienced employees at Abiomed Inc., Machine Solutions (Valve 
crimping device) was recommended as a transcathether heart valve crimping equipment provider.  Their 
three devices that would be suitable were the HV200, HV 500 and HV 950, shown by Figure 3.8 and 
Figure 3.9. The catalogue pages and the detailed specifications of each crimper can be found under 
Appendix D of this report. 
Figure 3.6: Generic Stent in a 10mm OD tube 
Figure 3.7: Uneven Strut Deformation 
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Figure 3.9: Machine Solutions HV 200/950 (Crimper Catalogue) 
   
 The HV 200 was the cheapest of all three but it only accepted stents with a diameter of up to 
34mm, which was relatively close to the size of our stents.  The HV 950 was too expensive and it would 
not have been utilized to its full potential.  The HV 500 was found to be most appropriate for the 
purposes of this project because of the following: 
1. 1mm to 50mm diameter range 
2. 90mm maximum specimen length 
3. Reasonable Cost  
Figure 3.8: Machine Solutions HV 200 (Crimper Catalogue) 
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However, there was a two weeks to one month lead time on the crimper from Machine 
Solutions.  In the meantime, the polyurethane valve was removed from the Generic Curve Stent and 
using the threads, it was pulled into the funnel.  The goal of this experiment was to assess any damage 
caused to the struts after observing the uneven pattern under the crimped down configuration.  Strut 
fracture resulted from pulling the Generic Curved stent into the 18 French funnel.  Figure 3. and Figure 
3. show the Generic Curved Stent after strut fracture.  The fractured struts have been pulled out for 
effect.   
 
Figure 3.10: Broken struts from Generic Curved Stent - vertical 
 
Figure 3.11: Broken struts from Generic Curved Stent – horizontal 
  When the crimper was received roughly three weeks later, the Generic Straight and Generic 
Crown stents were successfully crimped down to 24 French sizes without a polyurethane valve.  After 
the valve leaflets had been attached using the dip casting technique, the stents were successfully 
crimped down to 26 French sizes.  A more uniform stent pattern was observed under the crimped down 
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configuration which confirmed our theory that it was the unorthodox crimping method that created the 
irregular pattern, and eventually caused failure, for the Generic Curved stent. 
According to the information obtained during background research, the starting raw tube size 
should be slightly smaller than the targeted crimp down size.  Since the Generic Straight and Crown 
stents were effectively crimped down to 24 French, it was assumed that they were made from 20 – 22 
French raw tubes.  Crimping the stents with and without the valve leaflets allowed the team insight into 
the amount by which the valve leaflets increase the stent profile, that is, 2 French.    
From earlier observations and the strut failure, a stent with the following specifications would 
be most appropriate to reach the 18French crimp down size target. 
- 12 – 14 French raw tubing start size 
- 0.5mm strut thickness 
- 15 apexes 
The strut thickness and number of apexes were chosen to be values between that of the Generic 
Straight and Generic Curved stents.  The Generic Curved stent was the only stent that was successfully 
crimped down to an 18 French size but seemed to lack radial stiffness.  For the stent and valve assembly 
to be successfully crimped down to an 18 French diameter size, the size of the starting tube has to be 12 
– 14Fr.  Since the Generic Curved Stent experienced fracture, the next stent generation will be made 
thicker for extra resistance to compressive stresses. Last observation was the seemingly lack of radial 
stiffness of the Generic Curved but over stiffness of the Generic Straight stent, 15 apexes will feature on 
the new stent iterations.      
On top of these design criteria, the team needed more experience with valve attachment 
techniques to model a new generation of stents that would not only be crimpable to 18 French diameter 
size, but also enable secure attachment to the polyurethane valve.   
 
Valve Attachment 
 Abiomed Inc. is experienced with the making and attachment of polyurethane valves due to 
their other products being currently commercialized.  While there may be other, potentially more 
appropriate attachment techniques, due to the sponsor’s familiarity with the proposed techniques, 
monetary and time constraints, the design team sought to get familiar with the four attachment 
techniques suggested and to identify the two most promising ones.  Once these have been established, 
stents can be designed with features to enhance the efficiency of these attachment methods.   
Dip Casting 
 Dip casting essentially consists of placing the stent over the preformed valve leaflet and dipping 
the assembly into the AngioflexTM solution.  The procedures for dip casting include the following: 
1. After the valve leaflet is manufactured and cured, the top of the valve leaflet is trimmed with a 
sharp blade, as shown by Figure 3.. 
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Figure 3.12: Trimming cured Angioflex
TM
 off the top flat surface on the mandrel 
2. Once the top is removed and a skirt length (typically around 10-15mm) is chosen, the 
polyurethane is cut at that position as seen in Figure 3.13. 
 
Figure 3.183: Trimming skirt from mandrel sides 
3. The stent is then placed over the mandrel and the whole assembly is dipped into the AngioflexTM 
solution using the same setup as described in the Polyurethane Valve Manufacture section.  The 
stent will be kept in place by frictional forces between the stent and layer of polyurethane on 
the steel mandrel. 
4. The dipping process can be repeated as many times as deemed necessary.  Repeating the 
dipping process makes the outer layer of polyurethane stronger but also adds to the profile of 
the stent.  Two dips were arbitrarily chosen as the most appropriate in terms of bond strength 
and material thickness.  In between each dip, a curing period of 20 minutes must be allowed. 
5. Once the outer layer has been cured, the mandrel is placed in a water bath at 37oC for an hour.  
The water bath separates the valve leaflet from the mandrel.  
6. The mandrel is taken out of the bath and dried with a paper towel before using a spatula to 
separate it completely from the mandrel. Refer to Figure 3.3 from page 34.  
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After the valve leaflet has been attached, it can be dissolved from the stent using a solvent, 
which cannot be disclosed for proprietary reasons.  The valve assembly is dipped in the solvent for five 
minutes before being washed under warm water.  After several trials with the Generic Crown and 
Generic Straight Stent, this attachment method was deemed unsuitable for this application.  While the 
bonds formed are very sturdy, the AngioflexTM gets webbed in between the struts thereby preventing 
crimping.    
Solvent Bonding 
 Abiomed Inc. uses solvents such as TetraHydroFuran (THF) to bond plastic parts together.  When 
applied on the parts that need to be bonded together, THF melts the surfaces and as they get pressed 
together, they solidify as one part.  This same principle was explored to attach the valve leaflet to the 
stent. 
 The beginning of the process is the same as the first three steps of dip casting.  However, the 
outer sleeve is formed differently.  The process is outlined below: 
1. A circular mandrel made out of delrin is dipped into the polyurethane solution on a similar setup 
as the steel mandrel.   
2. Once the sleeve is formed and cured on the mandrel, the assembly is placed in an oven at 100oC 
for an hour to get rid of surface deformities. 
3. The mandrel is then placed in a water bath at 37oC for an hour.   
4. The mandrel is taken out of the water bath, dried with a paper towel and the top is trimmed as 
shown by Figure 3.19. 
 
Figure 3.194: Trimming and removing top layer of sleeve from mandrel 
5. A polyurethane stent is then placed on the sleeve and adjusted until it is resting about halfway 
down the length of the sleeve (Figure 3.). 
42 
 
 
Figure 3.15: Polyurethane stent placed on exterior sleeve mandrel 
6. A fine tip marker is used to trace the upper contour of the polyurethane stent. Figure 3. shows a 
picture of the sleeve mandrel with the upper contour trace marks. 
 
Figure 3.16: Crown shape traced on exterior sleeve 
7. The mandrel is screwed off from the base and doing so shears off the lower end of the sleeve in 
a surprisingly neat manner. 
8. A spatula is then used to separate the sleeve from the mandrel.  Pouring rubbing alcohol while 
using the spatula makes the AngioflexTM more flexible and facilitates separation (see Figure 3.). 
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Figure 3.17: Separating sleeve from mandrel using spatula and alcohol 
9. The sleeve is then rolled out of the mandrel and laid flat so that the appropriate skirt length can 
be cut using a pair of scissors. 
10. The contours marked with the fine tip are cut out using the scissors. 
11. The sleeve is cut into a flat sheet at the lowest inflection point of any of the three curves.   
The remaining steps were to solvent bond a polyurethane valve into a Nitinol stent. This had not 
been attempted before.    
12. Next would be to use a solvent approved paintbrush and apply a solvent (the specific solvent 
cannot be disclosed due to proprietary rights by Abiomed Inc.)  onto the valve leaflet and the 
flat sleeve sheet.   
13. Place the flat sleeve sheet at the right spot around the Nitinol stent so that the wet surfaces 
would be in contact. Special precaution should be taken to correctly align the cut edges. 
14. As a first step, Teflon tape would then be used to apply pressure onto the two layers of 
AngioflexTM as they solidify back together.   
The solvent has a working time of roughly 1 – 2 hours as opposed to THF which has a working 
time of less than 10 seconds.  (Note: The working time of a solvent is the time elapsed between when 
the surface starts to melt and when the surface solidifies again.) Maintaining pressure during curing is 
essential to the success of solvent bonding.  Specially designed fixtures are available on other 
production lines to ensure that a uniform and constant pressure is being applied during the working 
time of the solvent.  The design team viewed this need as a potential means to remove bubbles of air 
that tend to get trapped when two surfaces are mated together.   
The first idea was to place the assembly in a vacuum chamber so that the air would be sucked 
out of the inner layer of AngioflexTM (the valve leaflet) and the outer layer (the sleeve).  The reasoning 
was based on a Ziploc bag which has its two sides pulled together over the food item as air is drawn 
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away from it.  However, drawing a vacuum requires that there is only one opening and that is not the 
case for the current assembly. 
Instead of drawing a vacuum, a pressure was thought to be the solution.  By applying a pressure, 
the air bubbles would be driven out of the two layers of polyurethane which would also be pressed 
together.  This assumption was based on the increased pressure exerted as an object sinks to bottom of 
the ocean.  A submarine for instance, would get crushed and see all the air bubbles move to an area of 
lower pressure should it not have been built with specially designed materials.  The team then 
proceeded to find a pressure chamber and connecting it to an air supply and a barometer.  Specific 
values for time and pressure were not yet determined as this was the first attempt. 
However, as soon as the sleeve got in contact with the solvent, it lost significant stiffness and 
placing it over the Nitinol stent proved rather difficult.  When the Teflon tape was placed over the two 
layers for initial support, the sleeve started to melt into the tape.  The team decided that the amount of 
solvent used was the root cause and the experiment was repeated using less solvent but the same 
results were observed.  Because of the poor results obtained, the team decided that solvent bonding 
was not a viable attachment method for the valve assembly being developed.   
Suturing 
 Suturing is a common attachment technique used to attach tissue valves to a Nitinol frame.  
Abiomed Inc. employs clean room operators who have experience suturing AngioflexTM and consulting 
them provided several important design considerations.   
The thread and needle that they use to suture have a diameter of 0.4mm.  Therefore, if the 
team decides to pursue suturing as an attachment method, the stent will require features with openings 
no smaller than 0.5mm that will allow the thread and needle to go through. 
Another relevant point that was brought up during the meeting was the fact that the Abiomed 
Inc. percutaneous valve is too soft for suturing.  Another material should be added during the valve 
manufacture to increase its stiffness and most importantly, prevent backflow leakage (Backflow leakage 
is discussed under the Testing section of this report).  Currently on the market is the Cribier-Edwards 
Percutaneous valve (see Figure 3.) which makes use of a fabric cuff (Webb, 2006) as well. 
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Figure 3.18: Cribier-Edwards Percutaneous Valve (Webb, 2006) 
 Suturing is a rather time consuming process and the design team had to ask the floor manager 
for his employee’s time.  As a result, suturing was tried on only the Generic Crown stent.  To prevent 
backflow leakage, a piece of fabric was placed in between the valve leaflet and the Nitinol stent before 
suturing.  Also, to prevent thread migration on the curved part of the stent, velour sewing cuff similar to 
the one used on the Abiomed Inc. Surgical Valve (refer to Figure 2.32 on page 29) was placed along the 
curved strut. Figure 3. shows a picture of the resulting assembly.   
 
Figure 3.19: Generic Crown Stent with Sutured Valve 
Two main conclusions can be drawn from the prototype.  The sewing cuff adds too much to the 
profile of the stent and shown be avoided if possible.  If the design team is to model a stent that has a 
crown-like member, it should have features that will prevent the threads from migrating along it.  The 
second inference is that the fabric adds too much to the profile of the stent.  A thinner material that will 
perform the same functions should be identified. 
Suturing remains one of the top attachment techniques.  While some problems are identified 
with the current prototype, these can be fixed for the next iteration.  If done correctly, the presence of 
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threads and knots does not add much to the profile and it provides for a secure means of attaching the 
leaflet to the Nitinol Stent.   
 
Thermoforming 
The thermoforming attachment technique follows the same steps as solvent bonding up until 
the contours of the sleeve are cut out.  Instead of cutting the sleeve into a flat sheet, the following steps 
are carried out: 
1. The contour marks are washed off with rubbing alcohol. 
2. The sleeve is carefully placed over the stent so that the commissure posts of the valve 
leaflet and those of the sleeve match (see Figure 3.). 
 
Figure 3.20: External sleeve on stent and aligned with mandrel commissure tips 
3. A piece of PTFE heat shrink tube is cut and placed over the stent as shown by Figure 3.. 
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Figure 3.21: PTFE heat shrink tubing 
Heat shrink tube shrinks at a certain temperature and as it does, it applies pressure on any 
object that is resisting the decrease in size. Heat shrink tubing is typically used to provide a protective 
layer against heat, corrosion, shock, moisture and other critical environmental conditions (Zeus, 2011).  
The PTFE tubing used has a shrink ratio of 4:1 with an ordered inner diameter of 25.4mm. Zeus specifies 
a 340oC recovery temperature and reports an inner diameter of 7.06mm after complete recovery.  The 
size was chosen as it was the closest one bigger than the diameter of the stents under assessment 
(approximately 25mm diameter).  The shrink ratio was preferred over the 2:1 as it would apply more 
pressure as it tried to recover under the application of heat.   
4. The mandrel and valve assembly are placed on a rotator.  
5. A Steinel heat gun is used to apply heat onto the valve assembly to bond the valve leaflet 
and outer sleeve, see Figure 3..   
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Figure 3.22: Steinhel heat gun 
Applying heat melts and bonds the valve leaflet and outer sleeve together while causing the 
heat shrink tubing to contract and exert pressure on the sleeve. The first trials were completed by 
placing the assembly in an oven at 340oC (the heat shrink tubing recovery temperature) but the uniform 
distribution of heat was undesired for this application.  The polyurethane valve leaflets get deformed 
under the application of heat.  This deformation will presumably affect their closing/opening abilities 
which will in turn impede their hemodynamic performance.  Moreover, the optimum time to leave the 
stent in the oven was unknown.  By leaving the stent in the oven for too long increases the risk of over 
melting the layers of AngioflexTM.  Over melting introduces the risk of affecting the uniform thickness of 
the valve leaflet and outer sleeve leaving creating weak attachment points.  If the assembly is not left in 
the oven for long enough, the valve leaflet and outer sleeve do not have enough time to melt and bond 
together. 
The heat gun used is a HG 2000E from Steinel and has a temperature range of 90oC to 570oC.  
Using the heat gun allowed the team members to vary the amount of heat, apply heat to the desired 
position for the required amount of time and visual feedback was available.  When using the heat gun, 
the heat shrink tubing contracts almost instantly to form a snug fit with the valve assembly.  When the 
sleeve melts onto the valve leaflet, the struts become more pronounced and the heat shrink forms an 
even tighter seal over the stent.  The area under heat is typically melted together when this second 
contraction typically occurs.  At this point, the heat was directed at a different point as the stent 
continued its rotation.  The areas that needed most time under the heat gun were areas where 
attachment was crucial, in other words, along the commissure posts, the valve leaflet contours and at 
the bottom of the valve skirt. 
As observed after the valve assembly was removed from the oven, the valve leaflets would be 
deformed.  To avoid deformation, compressed air is continually blown at the valve leaflets as heat is 
applied at the various locations. Figure 3. shows the thermoforming arrangement.             
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Figure 3.23: Thermoforming arrangement 
 After the outer sleeve and valve leaflets have been bonded, the mandrel and valve are allowed 
to cool for one hour.  After that the heat shrink tubing is cut and removed.  The rest of the post 
thermoform procedure is the same as the post dip casting processes. 
 Upon inspection, the commissure tips were found to be somewhat weak. A 1cc syringe with an 
applicator tip was used to apply two drops of AngioflexTM at each commissure posts.  After curing, these 
points were found to be much stronger.   
The overall strength of the Nitinol to polyurethane was also found to be somewhat poor.  To 
increase the efficiency of the bond, a primer was used.  The most suitable primer was found to be 
Cilbond 49SF (refer to Appendix E for the technical data sheet).  “Cilbond® 49SF is the industry standard 
bonding system for hot-cast high performance PU elastomer systems and TPU’s.  Recommended by 
many PU system houses worldwide, Cilbond 49SF offers unbeatable performance in the toughest 
environments.” (Vita, 2011).   
To prime the stent, forceps were used to clamp its top. The stent was slowly lowered into a 
beaker containing the Cilbond 49SF solution for 20 seconds.  The primed stent was placed in an oven at 
100oC and allowed to cure overnight.  The thermoforming process was repeated with the primed stents.  
The bond was noticeably stronger but the drops of AngioflexTM at the commissure tips were still needed. 
Due to the low increase in stent profile, manufacturability of process and efficiency, 
thermoforming was retained as one of the two most viable attachment techniques.  After careful review 
of the results, the design team concluded that thermoforming did not require the stent to have any 
special features on top of the ones already identified.      
Stent Development 
 Along with experimenting with valve attachment techniques, the design team worked closely 
with Admedes GmbH to identify what information was needed for them to manufacture the Nitinol 
stent.  They made it clear that if the team wanted feedback on the stent designs before they were 
manufactured, the 3D models would have to be generated in SolidWorks.  To manufacture the stents, 
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Admedes GmbH requires an as-cut model of the stent.  An as-cut model of the stent is a flat pattern of 
the stent when it is cut from the starting tube.  For instance, if a 40mm long 12 French (4.0mm) starting 
tube is specified to the manufacturer, the stent pattern should be drawn onto a rectangular sheet with 
the following dimensions: 
- The length of the rectangle should be equal to the length of tube specified to the manufacturer.  
In this case, the length of the rectangle is 40mm.   
The design team acknowledges the fact that the length of the tube changes as the stent is 
thermally processed to achieve the desired final diameter.  However, for the purpose of proving 
feasibility of concept it was safe to overlook this change. 
- The width of the rectangle corresponds to the circumference of the tube.  A tube with a 4.0mm 
diameter has a circumference of 12.568mm (                    ).  Therefore, the 
width of the rectangle has to be 12.568mm. 
3D models will be generated using the final tube size which would then be used to create the as-
cut models once the order was finalized.  Careful attention will have to be paid when shrinking the 
horizontal dimensions when the as-cut model is created from the 3D part.  
3D Modeling 
 Admedes GmbH sent over a SolidWorks part to illustrate their way of generating a 3D model of 
a Nitinol stent.  However, Admedes GmbH uses SolidWorks 2010 and Abiomed Inc. only has licensing 
rights to the 2006 version of the software.  The most effective approach was to open the file at 
Worcester Polytechnic Institute (WPI).  Subsequently, all CAD related work was completed at WPI. 
 Admedes starts the process by creating a hollow tube with the specified expanded diameter and 
thickness, see Figure 3.. 
 
Figure 3.24: Admedes step 1 - Tube extrusion 
Their second step is to create a plane parallel to the length of the tube and tangent to the 
surface.  A Wrap feature is then created and the sketch is drawn on the plane.  The sketch is started at 
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the point where the plane is tangent to the tube to obtain the most accurate results.  The Wrap feature 
allows the user to sketch a pattern onto a plane before it is embossed to or debossed from a curve 
surface.  Figure 3. shows a normal view of the sketch and plane used in the Wrap feature and Figure 
3.26 shows an isometric view of the resulting after applying the Wrap feature. 
 
Figure 3.25: Normal view of sketch and plane 
 
Figure 3.26: Admedes step 2 - Isometric view of Wrap feature 
A circular pattern is then used to generate the pattern shown in Figure 3. followed by a cut-middle 
feature, Figure 3.. 
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Figure 3.27: Admedes step 3 - Circular pattern of wrap feature 
 
 
Figure 3.28: Admedes step 4 - cut-middle feature 
Lastly, the half stent is mirrored to create the full generic stent as shown by Figure 3.. 
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Figure 3.29: Admedes step 5 - mirror half stent 
The design team successfully created several iterations with the wrap feature, Figure 3. – Figure 3. 
 
Figure 3.30: Wrap iteration 1 
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Figure 3.31: Wrap iteration 2 
 
Figure 3.32: Wrap iteration 3 
However, as the design team introduced new features into the stent to meet the design criteria, 
the Wrap feature soon became very cumbersome and did not seem like the most effective and accurate 
way of modeling the stents.  The main source of error occurred when the sketch was not drawn where 
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the plane was a tangent to the tube.  Taking reference geometries based on the tube was misleading 
and new means of creating the stent were investigated. 
The Flex feature was tried as the user could create the cut on a flat sheet, hence eliminating the 
source of error noticed when using the Wrap feature. The Flex feature seemed very intuitive and user 
friendly as shown by the complex cut that was created under one sketch, Figure 3.. 
 
Figure 3.33: Sketch for Flex feature 
 Applying the Flex feature rotates the sheet about a specified axis and with a correctly placed 
axis; the sheet is flexed on itself to create a stent. However, as shown by Figure 3.34, a perfect cylinder 
is not created.  The Flex feature could not be used as a stent generated using the Flex feature would not 
be suitable for FEA.  
56 
 
 
Figure 3.34: Open connection with Flex feature 
  As a result, a new feature had to be identified to properly model the stent.  The Sheet Metal 
Feature was used.  To illustrate how it is used, one of the final two iterations that were ordered to be 
manufactured will be detailed.   
1. Model a hollow tube with the inner and outer diameter specified for the stent size in the 
expanded configuration, Figure 3.35. 
 
Figure 3.35: Sheet metal step 1 
57 
 
2. Cut out two-thirds of the tube along its length, Figure 3.. 
 
Figure 3.36: Sheet metal step 2 
3. Create a sheet metal from the one-third tube and flatten into a rectangle, Figure 3. 
 
Figure 3.37: Sheet metal step 3 
4. Once a flat sheet is obtained, it is easy to create any complex geometry accurately.  When 
creating the pattern, it is sometimes natural to assume that this is the full stent but that is not 
the case.  The rectangle shown represents only one-third of the entire stent. Figure 3. shows the 
pattern created on the flat sheet for the Half Diamond 1 stent.  
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Figure 3.38: Sheet metal step 4 
5. The flat sheet can then be curved back into the one-third tubing, see Figure 3.. 
 
Figure 3.39: Sheet metal step 4 
6. An assembly is then created where the three thirds are mated together to form a full stent, 
Figure 3.. 
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Figure 3.40: Sheet metal - finished assembly 
The Half Diamond 1 stent uses a half diamond pattern similar to the Cribier-Edwards 
Percutaneous Heart valve.  Exact dimensions for the stent cannot be disclosed at this point.  The 
reasoning behind each feature is explained below: 
- The vertical struts were placed at 120o intervals to act as support for the commissure posts.  
They run through the whole length of the stent for added rigidity and to allow for a broader 
range where the valve can be located in the stent.  The rectangular windows will prevent thread 
migration if suturing is used and will allow the valve leaflet and outer sleeve to make contact 
and create a better seal with the Nitinol frame.  
- The Half Diamond 1 is a relatively short stent.  Short stents were thought to risk being tilted 
during use but due to severe aortic stenosis, the natural valve becomes very stiff and tilting can 
be considered to be low risk.   
- An open cell pattern is used (except for the middle row) to minimize pinching of the AngioflexTM 
layers as the stent is crimped down.  When the two layers of polyurethane are thermoformed 
together, they form webs between four neighboring struts.  As the stent crimps down, these can 
act as scissor blades and potentially damage the polyurethane. 
- The open cell pattern is radially weak by principle because of the decreased number of linked 
struts.  However, the increased number of apexes promotes the anchoring aptitude to the aortic 
valve. 
- To relieve stress at the apexes, a track-like pattern is used instead of a keyhole pattern (refer to 
Background section).  This feature was recommended by Admedes GmbH as they had seen it 
work better with stents similar to the Half Diamond 1.     
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The Crown Stent 1 was the second stent iteration ordered.  It is based off of the Generic Crown 
1 stent.  Figure 3. through Figure 3. show strategic views of the stent. 
 
Figure 3.41: Isometric view of Crown Stent 1 
 
Figure 3.42: Dimetric view of Crown Stent 1 
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Figure 3.43: Front view of Crown Stent 1 
 
 
Figure 3.44: Right view of Crown Stent 1 
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      The reasoning behind each design criteria is explained here, however, the specific dimensions of 
the Crown Stent 1 cannot be disclosed due to proprietary rights currently owned by Abiomed Inc. 
- The top part of the stent is added as the commissure tips for the Generic Crown 1 stent were 
very flexible.  The top stent will provide more radial stiffness and will decrease commissure 
posts movement during use. 
- The vertical struts are not well supported and the team understands that this represents a 
potential weakness. As a result, a closed cell pattern is used as it is more radially stiff and is 
acceptable for this design as the valve leaflet will not be webbed in between the struts.  The 
valve leaflet will be limited to the middle part and potentially the top half of the first row of 
stents. 
- The path of the corn-like member is meant to follow the contour of the valve leaflet and provide 
extra support. 
- Along the crown-like member, there are seven inflexion points to prevent thread migration.  The 
inflexion parts are also present to act as predictable points for the member to flex. 
- The lowest inflexion point is placed above an area where there is no apex from the bottom 
stent.  This was done to allow enough clearance as during crimping, the apex will be lowered to 
allow for the decrease in diameter size.   
- The reasoning for using the rectangular windows along the strut is the same as the Half 
Diamond 1 stent.      
 
As-Cut Models 
After these designs were converged on, as-cut models were created.  These were relatively 
simple to generate.  The outside diameter of the stent under expanded configuration was specified to 
be 23mm.  A 14 French (4.7mm) raw tube size was specified. Therefore, when creating the as-cut 
drawings, the horizontal dimensions were reduced by a factor of (23.0 ÷ 4.7 = 4.89) 4.89.  Admedes 
GmbH is somewhat versatile regarding the as-cut drawings.  As seen in Figures 45-46, either a sketch or 
a flat sheet will be accepted.    
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Figure 3.45: As-cut drawing for Crown Stent 1 
 
 
Figure 3.46: As-cut drawing for Half Diamond 1 
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Test Setup and Results  
 The following sections detail the effort of the team to assess the theories that have been put 
forward in the previously by testing the Half Diamond 1 and Crown Stent 1.  Finite Element Analysis will 
be performed while Admedes manufactures and ships the stents.  Once the prototypes are received, the 
efficacy of the valve attachment techniques will be evaluated.  If deemed adequate, bench-top testing 
will follow and ultimately cycle testing will be performed.  
FEA Analysis 
Admedes GmbH has a one week turnaround time to manufacture and mail the stents after the 
order and all required information has been received.  In the meantime, the team attempted to conduct 
a finite element analysis of the Half Diamond 1 and Crown Stent 1 models.  ANSYS Workbench 12.1 will 
be used as it is the only FEM package that Abiomed Inc.  has licensing rights to.     
Nitinol Model 
 Nitinol possesses very unique material properties.  As such, a new material model must be 
created in ANSYS Workbench 12.1 to obtain satisfactory results.  The team understands that Nitinol can 
have very different properties depending on the thermal processing it is subjected to after being cut.  
For extremely accurate results, a sample of the Nitinol tubing must be tested for the various parameters 
listed below: 
- Density 
- Coefficient of thermal expansion at different temperatures 
- Reference temperature value 
- Stress vs. strain data points 
- Mooney-Rivlin 2 Parameters 
o Material constant C10 
o Material constant C01 
o Incompressibility parameter 
- Tensile yield strength 
- Tensile ultimate strength 
For the purpose of this project, the valve attachment and bench-top equipment will have the 
most weight in terms of evaluating the stent performance.  However, getting acquainted with the 
implications of conducting a finite element analysis on a Nitinol stent is a very important skill to have in 
the later stages of stent design. 
Abiomed Inc. uses Nitinol in other products and has conducted FEA on these parts.  The generic 
Nitinol model available will be used to analyze the Half Diamond 1 and Crown Stent 1 models.  The 
properties listed in the model are: 
- Density: 6500 kg/m3 
- Coefficient of thermal expansion at different temperatures: table empty 
- Reference temperature value: 22oC 
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- Stress vs. strain data points: see Table 4.1 and Figure 4.1 
- Mooney-Rivlin 2 Parameters 
o Material constant C10: -2.5326 X 1010 Pa 
o Material constant C01: 2.9905 X 1010 Pa 
o Incompressibility parameter: 0 Pa-1 
- Tensile yield strength: 9.3 X 108 Pa 
- Tensile ultimate strength: 1.1 X 109 Pa 
Table 4.1: Stress vs. strain data points for Nitinol model 
Strain (m/m) Stress (X 108 Pa) 
0 0.0  
0.01 4.0  
0.02 6.0  
0.03 7.0  
0.04 7.8  
0.05 8.3  
0.06 8.7  
0.07 9.0  
0.08 9.3  
0.09 9.6  
0.10 9.9  
0.11 10.5  
0.12 11.0 
 
 
Figure 4.1: Stress vs. strain diagram for Nitinol 
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ANSYS Workbench 12.1 
 The first obstacle encountered using ANSYS was that the SolidWorks files could not be properly 
imported for unknown reasons.  The SolidWork Assembly file was converted into the Parasolid format 
which had better compatibility with ANSYS.  After adding the Nitinol model to the Materials library and 
importing the Half Diamond 1 Parasolid file as the geometry, Mechanical was opened to specify material 
properties, connection types, support configuration, load type and the desired output.   When the file is 
opened, the stent is shown as three distinct parts bonded together at three contact regions.  This 
subsection lists the different combinations of settings tried with the outcome of each. 
Condition 1 
Part: Half Diamond 1 
File Type: Parasolid file created from a SolidWorks Assembly file 
Material: Structural Steel 
Connection Type: Bonded 
Load Type: Pressure 
Load Magnitude: 100 Pa 
Support Type: Frictionless 
Support Location: Top flat part of 3 vertical struts 
Solution Type: Total deformation 
Warning messages:  
1. One or more bodies may be underconstrained and experiencing rigid body motion. Weak 
springs have been added to attain a solution.  Refer to Troubleshooting in the Help System for 
more details. 
2. At least one body has been found to have only 1 element in at least 2 directions along with 
reduced integration.  This situation can lead to invalid results.  Consider changing to full 
integration element control or meshing with more elements.  Refer to Troubleshooting in the 
Help System for more details. 
Results: 
Figure 4. and 4.3 show a very odd pressure distribution.  The stent is crimped in an irregular pattern and 
the stress is not symmetrical about the vertical struts.   
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Figure 4.2: Top view of condition 1 results 
 
Figure 4.3: 3D view of condition 1 results 
Discussion:        
- Considering the warning messages, the irregular stress distribution does not seem very out of 
place. 
- Because of the ambiguity of the results, the next step was to apply pressure on a tube.  The tube 
will be made as 1 solid object and the support conditions will be analyzed. 
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Condition 2 
Part: 1 piece 23mm hollow tube 
File Type: Parasolid file created from a SolidWorks Part file 
Material: Structural Steel 
Connection Type: n/a 
Load Type: Pressure 
Load Magnitude: 100 Pa 
Support Type: none 
Support Location: n/a 
Solution Type: Total deformation 
Warning messages:  
1. One or more bodies may be underconstrained and experiencing rigid body motion. Weak 
springs have been added to attain a solution.  Refer to Troubleshooting in the Help System for 
more details. 
Results: 
 
Figure 4.4: front view of condition 2 results 
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Discussion: 
- Before this run, frictionless supports were used at the top of the tube.  It created a pressure 
gradient from the top to the bottom. 
- Despite the error message, the pressure distribution seems logical (Figure 4.4) based on best 
engineering judgment.  These seem to be the right conditions for analyzing the stent. 
- Since the stent is being viewed as three distinct parts bonded together, the tube will be 
modeled the same way. 
Condition 3 
Part: 3 pieces 23mm hollow tube assembly 
File Type: Parasolid file created from a SolidWorks Assembly file 
Material: Structural Steel 
Connection Type: bonded 
Load Type: Pressure 
Load Magnitude: 100 Pa 
Support Type: none 
Support Location: n/a 
Solution Type: Total deformation 
Warning messages:  
1. One or more bodies may be underconstrained and experiencing rigid body motion. Weak 
springs have been added to attain a solution.  Refer to Troubleshooting in the Help System for 
more details. 
Results: 
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Figure 4.5: Isometric view of condition 3 results 
Discussion: 
- Various connection types were experimented with Bonded seems to be the most appropriate.  
Separation of parts occurs with the other connection types. 
- It is now clear that ANSYS has trouble treating the three bodies as one, see Figure 4.5.  The next 
step should be to create a one part stent in SolidWorks. 
Due to a lack of time, this path was not further explored.  The Future Works section of this report 
outlines potential ways to create a one part stent that could potentially yield sensible results when 
subjected to a pressure load in ANSYS. 
 
Stent Preparation for Testing 
Crimper 
The first test that the Half Diamond 1 and Crown Stent 1 iterations were subjected to was the 
crimp test.  Both the Half Diamond 1 and Crown Stent 1 were successfully crimped down to 16 French 
diameter sizes.  This was excellent news as it meant that there was room for the valve leaflet before 
reaching the 18 French upper limit size.    
Thermoforming 
 The valve leaflets were then thermoformed onto the stents to assess their features that were 
meant to enhance the technique.  Figure 4. and Figure 4. show the results of the thermoforming valve 
attachment test.   
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Figure 4.6: Thermoformed Crown Stent 1 
 
Figure 4.7: Thermoformed Half Diamond 1 
The second part of the attachment test was to evaluate the minimum crimp down size of the stents with 
the leaflets attached and to inspect for any visual damage.   
Half Diamond 1 Results and Discussion: 
- Successfully crimped down to 18 French with thermoformed valve leaflets 
- Crimper did not seem to do any damage to stent, valve or attachment.  
- Stent does not require much force to be crimped down to 18 French. 
- The stent does feel like it is missing some radial stiffness and that might cause anchoring issues.  
The design intent was to have more apexes that would allow the stent to anchor better to the 
aortic node so that the stent would not be relying extensively on radial stiffness. 
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- Overall, it can be concluded that the Half Diamond 1 passed this test. 
Crown Stent 1 Results and Discussion: 
- Successfully crimped down to 18 French with thermoformed valve leaflets 
- Figure 4. and Figure 4. show the extent of the damage caused by the crimper.  The bottom of 
the valve skirt came off the stent.  The lowest inflexion point on the crown-like member seems 
too sharp and can potentially rupture the valve leaflet.  The fact that it bows out so much also 
increases the pressure that it exerts on the valve leaflet.   
- The design intent was that the valve leaflet would only be in contact with the first row of the 
bottom stent.  However, the connection point of the crown member and vertical strut is too 
high and the top stent interferes with the valve leaflet during crimping. 
- The three vertical struts seem very likely to fail in torsion. 
- While the stent was effectively crimped down to an 18 French size, the damage sustained was 
considerable.  The different attachment technique should reveal if the stent is a bad design or is 
thermoforming not the right type of attachment for it.     
 
Figure 4.8: Post collapsed thermoformed Crown Stent 1 - view 1 
 
Figure 4.9: Post collapsed thermoformed Crown Stent 1 - view 2 
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Suturing 
 For this iteration, a polyester sheet was used instead of fabric and no sewing cuff was needed.  
The polyester sheet is placed on the circular mandrel and the polyurethane valve placed over it to trace 
the valve leaflet contour with a fine tip.  The polyester sheet is placed on the steel mandrel in between 
the second and third dip so that it is enclosed within the valve.   
Half Diamond 1 Results and Discussion: 
 
Figure 4.10: Sutured Half Diamond 1 - view 1 
 
Figure 4.11: Sutured Half Diamond 1 - view 2 
- With the polyester sheet, the profile is much less than with the fabric and the stent was 
successfully crimped down to an 18 French diameter size. 
- There seems to be no visible sign of damage after crimping, see Figure 4. and Figure 4.. 
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Crown Stent 1 Results and Discussion: 
 
Figure 4.12: Sutured Crown Stent 1 - view 1 
 
 
Figure 4.13: Sutured Crown Stent 1 - view 2 
 
- Crown Stent 1 with the sutured valves look really clean. 
- There seems to be no visible sign of damage after crimping, see Figure 4. and Figure 4..  The 
bowing of the member is somewhat contained with the valve being on the inside.  Also, there is 
no risk of the member puncturing the valve leaflet. 
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Bench-top Testing 
 To further evaluate the performance of the stent, valve leaflet and valve attachment, Abiomed 
Inc. has a series of bench-top test equipment that was designed to test the surgical valves.  However, 
slight modifications to the mounts made them suitable for the purpose of this project.  The benchmark 
values that the design team is trying to make are based off of the values that the surgical valve is 
currently expected to exceed.  Due to the confidential nature of this project, actual test results will not 
be included but the information drawn from the test results is presented. 
 
Dynamics 
 The dynamics tester places the valve under real life simulation with a forward pressure of 
120mm Hg and backward pressure of 85mm Hg.  A camera is placed directly above the valve and the 
opening/closing of the valve leaflets is monitored.  The dynamics tester evaluates the opening/closing 
mechanism of the valve leaflets but also the performance of the commissure posts and other valve 
supporting frames.   
 Both versions of the Half Diamond 1 stent performed as well as expected, with the valve leaflet 
maintaining a symmetrical shape during each phase.  This implies that the frame supports the valve 
leaflet well enough that no irregular movement of the leaflet is seen. 
 The Crown Stent 1 however, experienced more difficulties in the Dynamics tester.  The opening 
phase looked fine but during backflow the crown members cave in significantly, causing very inefficient 
valve leaflet movement.  The caving in of the members are most likely allowing significant amounts of 
back flow which will be confirmed with the Backflow tester.  This confirms the finding during crimping 
that the crown-like members need to be fastened to the lower stent to avoid bowing out and now, 
caving in. 
 
Pressure Drop 
 The Pressure Drop tester submits the valve to forward pressure around 120mm Hg.  It monitors 
the flow rate before and after the valve and uses its imbedded algorithm to calculate the pressure drop.  
It is mostly used to monitor the stiffness of the valve leaflet and does not really evaluate the 
performance of the stent.   
 The stents were tested and the Crown Stent 1’s saw a smaller pressure drop than the Half 
Diamond 1’s.  While the difference is not significant, it may be due to the partial deformation of the 
valve leaflets during thermoforming. 
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Backflow 
 The Backflow tester applies a backward pressure of 85mm Hg on the valve and monitors how 
much time is required for the water level to fall below two pre-determined marks.  This time is equated 
to a flow rate. 
 All stent iterations saw values below the target surgical valve values.  However, the Half 
Diamond 1 stents performed reasonably.  The bottom of the skirt was not sutured at enough points and 
allowed a leak path to form.  The leak path for the thermoformed Half Diamond 1 has not been 
identified yet.   
 The Crown Stent 1 stents performed terribly.  The same behavior as on the Dynamics Tester was 
observed and confirmed that the commissure posts are too flexible and that the crown-like member 
needs to be fixed to the bottom stent.    
  
Mock Circulatory Loop and Placement 
 The Mock Circulatory Loop and Placement Tester evaluates the delivery capabilities of the 
system but the design team did not have the resources to develop a delivery system.  The poor 
performance results of the valve meant that more time was to be devoted on developing new stent 
iterations that would address the faults observed. 
 
Cycle test 
 The cycle tester simulates aging of the stent, valve leaflet and attachment by vibrating the stents 
at 120Hz in a saline solution at 37oC and 120mm Hg.  The target is to reach 380M cycles which would 
occur after roughly 366 days if the tester was run continuously. 
Only one stent was placed in the cycle tester as the mount modification was complex and not enough 
time was left to create a new one.  After suturing the valve leaflet to the Generic Crown stent, the latter 
was placed in the cycle tester.  Valve rupture was observed about a month into the test, that is, 31M 
cycles, see Figure 4.. Since only one failure was observed, no conclusion could be drawn. 
 
Figure 4.14: Valve rupture in cycle tester  
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Discussion & Future Works 
Discussion  
After analysis of the data provided by the test results, the design team generated a list of action 
items that should be completed in the next phase of the project.  To put the list of future work action 
items in perspective, a brief outline of what has been accomplished so far is presented.    
-          Understand the unique properties of Nitinol  
-          Get acquainted with the design considerations involved in modeling a Nitinol stent 
-          Learn about the manufacturing processes involved in making a Nitinol stent 
-          Using the generic stents available, recognize the most suitable attachment techniques for this 
application 
-          Analyze the attachment techniques to generate stent features that would increase quality of 
attachment 
-          Learn how and create 3D models of stent iterations in SolidWorks 
-          Incorporate features into stent models to meet design specifications 
-          Evaluate stents, valve and attachment methods via bench-top testing equipment 
-          Analyze and present findings 
It is only after the careful execution of these steps that a coherent action plan may be developed for 
the next phase of this project.   
 
Future Works 
Crown Stent 1 
 The Crown Stent 1 seemed promising when the valve leaflet was sutured.  While it did fail the 
bench-top tests, it is a reasonable first iteration that can be a robust prototype once its current flaws are 
addressed.  
1. The lowest inflexion point on the crown-like member needs to be attached to the bottom stent.  
A flex connector could be used to join to inflexion point to the antinode on the stent directly 
below it. The flex connector should have a zigzag feature that will account for changes in height 
as the stent expands and gets crimped down. 
2.  The connection point between the crown-like member and the vertical strut is too high.  The 
next iteration should see that point lowered by 5mm. 
3. This iteration of the stent sees the crown-like member too steep.  On top of lowering the 
connecting point by 5mm the lowest inflection point should be moved vertically up by 2mm and 
the members should experience more of a curve to better support the valve leaflet contour. 
4. The vertical struts seem very prone to failing in torsion.  This fault should be dealt with before 
the next stent generation is ordered.   
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Half Diamond 1 
 The Half Diamond 1 stent was the most promising of the two iterations.  However, it is also the 
most difficult one to improve as the failure modes are still not understood. 
1. The addition of flex connectors at every other apex on the top and bottom row would add radial 
stiffness to the system. 
2. Testing with colored water at lower pressures should be performed.  This would enable the leak 
path to be identified and steps taken to address it. 
Finite Element Analysis 
 As the project gets closer to a final stent design that will have to meet all design specifications, 
Finite Element Modeling becomes a crucial skill.  For this project, more ways to create a 1 part stent 
could not be explored further but the team identified some potentials ways. 
1. After making the SolidWorks assembly model, save it as a part and create a Parasolid format file 
from the part file. 
2. After creating the one-third part of the stent, instead of making an assembly, use the circular 
pattern feature of SolidWorks to reproduce the part into a full stent. 
Cycle Tester       
 With a new round of stents being ordered after the current issues have been addressed, it is 
reasonable to assume that they will meet the test criteria.  The next step will be to test the stents under 
fatigue loading.  Ordering new mounts for the cycle tester is imperative to the smooth execution of the 
next step. 
Delivery System 
 At the beginning of the project, it was believed than an off-the-shelf delivery system could be 
adapted for use by the team.  However, with the intrinsic designs being developed, a delivery device 
suited to the stents need to be developed.  At the same time, the stents need features that will allow 
them to latch on to the introducer during the crimp down process. 
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Appendices 
Appendix A: Most Popular Stents 
 
Table 5.1: Popular NiTi self-expanding stents (Stoeckel, Bonsignore, & Duda, 2002) 
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Figure 5.1: Sheet-based Memotherm Stent with lap welded struts 
 
 
Figure 5.2: left - SMART Stent (Cordis), right - Memotherm Stent (Bard) 
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Figure 5.3: top - Jostent SelfX Stent (Jomed), bottom - Dynalink Stent (Guidant) 
 
 
 
Figure 5.4: Intracoil stent (IntraTherapeutics) 
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Figure 5.5: Cragg Stent 
 
 
Figure 5.6: Cook ZA knitted stent 
 
 
Figure 5.7: Welded Symphony Stent (BSC) 
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Appendix B: French Catheter Scale 
 
 
Figure 5.8: French catheter scale (not to scale) 
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Appendix C: Strut Measurements 
 
Strut Thickness 
 
Table 5.2: Generic stents thickness measurement 
Reading Number Generic Straight (mm) Generic Curved (mm) Generic Crown (mm) 
1 0.623 0.470 0.561 
2 0.631 0.468 0.560 
3 0.632 0.468 0.559 
4 0.629 0.472 0.559 
5 0.627 0.469 0.56 
6 0.629 0.471 0.562 
7 0.630 0.470 0.558 
8 0.630 0.467 0.56 
9 0.628 0.471 0.561 
10 0.628 0.470 0.56 
Exact Average 0.6289 0.4696 0.56 
Rounded up Average 0.63 0.47 0.56 
 
 
Strut Diameter 
 
Table 5.3: Generic stents diameter measurement 
Reading Number Generic Straight (mm) Generic Curved (mm) Generic Crown (mm) 
1 23.12 23.22 23.08 
2 23.09 23.19 23.10 
3 23.10 23.20 23.11 
4 23.09 23.18 23.11 
5 23.11 23.22 23.10 
Exact Average 23.102 23.202 23.1 
Rounded up Average 23.1 23.2 23.1 
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Appendix D: Machine Solution Crimper 
Product Specifications 
 
Figure 5.9: Machine solutions product specifications (Equipment Specifications) 
  
89 
 
Catalogue Pages 
 
 
Figure 5.10: Page 1 of Crimper Catalogue (Crimper Catalogue) 
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Figure 5.11: Page 2 of Crimper Catalogue (Crimper Catalogue) 
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Appendix E: Cilbond® 49SF Data Sheet (Vita, 2011) 
 
Figure 5.12: Page 1 of Cilbond 49SF data sheet 
92 
 
 
Figure 5.13: Page 2 of Cilbond 49SF data sheet 
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Figure 5.14: Page 3 of Cilbond 49SF data sheet 
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Figure 5.15: Page 4 of Cilbond 49SF data sheet 
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Figure 5.16: Page 5 of Cilbond 49SF data sheet 
